

# Salim Yusuf

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/9468106/salim-yusuf-publications-by-citations.pdf>

**Version:** 2023-06-07

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

953  
papers

153,337  
citations

187  
h-index

377  
g-index

1,079  
ext. papers

178,460  
ext. citations

13.9  
avg, IF

8.04  
L-index

#	Paper	IF	Citations
953	Dabigatran versus warfarin in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , <b>2009</b> , 361, 1139-51	18	7909
952	Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. <i>Lancet, The</i> , <b>2004</b> , 364, 937-52	11.5	7508
951	Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. <i>New England Journal of Medicine</i> , <b>1991</b> , 325, 293-302	18	5450
950	Beta blockade during and after myocardial infarction: an overview of the randomized trials. <i>Progress in Cardiovascular Diseases</i> , <b>1985</b> , 27, 335-71	1.9	2585
949	Telmisartan, ramipril, or both in patients at high risk for vascular events. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 1547-59	18	2573
948	Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. <i>Lancet, The</i> , <b>2001</b> , 358, 527-33	11.5	2571
947	Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. <i>Lancet, The</i> , <b>2003</b> , 362, 777-81	11.5	2087
946	Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. <i>Lancet, The</i> , <b>2005</b> , 366, 1640-9	11.5	2008
945	Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. <i>Lancet, The</i> , <b>2010</b> , 376, 112-23	11.5	1971
944	Global burden of cardiovascular diseases: part I: general considerations, the epidemiologic transition, risk factors, and impact of urbanization. <i>Circulation</i> , <b>2001</b> , 104, 2746-53	4.8	1924
943	Apixaban in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 806-17	18	1772
942	Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. <i>Lancet, The</i> , <b>2003</b> , 362, 759-66	11.5	1506
941	Association of psychosocial risk factors with risk of acute myocardial infarction in 11119 cases and 13648 controls from 52 countries (the INTERHEART study): case-control study. <i>Lancet, The</i> , <b>2004</b> , 364, 953-62	11.5	1504
940	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. <i>Lancet, The</i> , <b>2003</b> , 362, 767-71	11.5	1502
939	Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. <i>Lancet, The</i> , <b>2003</b> , 362, 772-6	11.5	1362
938	Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial. <i>Lancet, The</i> , <b>2011</b> , 377, 1409-20	11.5	1350
937	Homocysteine lowering with folic acid and B vitamins in vascular disease. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 1567-77	18	1332

936	Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. <i>Lancet, The</i> , <b>2008</b> , 372, 547-53	11.5	1179
935	Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. <i>Lancet, The</i> , <b>2000</b> , 355, 1575-81	11.5	1159
934	Reduction in fatal pulmonary embolism and venous thrombosis by perioperative administration of subcutaneous heparin. Overview of results of randomized trials in general, orthopedic, and urologic surgery. <i>New England Journal of Medicine</i> , <b>1988</b> , 318, 1162-73	18	1154
933	Basal insulin and cardiovascular and other outcomes in dysglycemia. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 319-28	18	1138
932	Rivaroxaban with or without Aspirin in Stable Cardiovascular Disease. <i>New England Journal of Medicine</i> , <b>2017</b> , 377, 1319-1330	18	1122
931	Adverse impact of bleeding on prognosis in patients with acute coronary syndromes. <i>Circulation</i> , <b>2006</b> , 114, 774-82	4.8	1020
930	Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 310, 959-68	7.4	992
929	Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. <i>Annals of Internal Medicine</i> , <b>2001</b> , 134, 629-36	2.5	962
928	Interpretation of the evidence for the efficacy and safety of statin therapy. <i>Lancet, The</i> , <b>2016</b> , 388, 2532-2561	11.5	961
927	The burden of disease in older people and implications for health policy and practice. <i>Lancet, The</i> , <b>2015</b> , 385, 549-62	11.5	947
926	Comparison of fondaparinux and enoxaparin in acute coronary syndromes. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 1464-76	18	922
925	Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. <i>Circulation</i> , <b>2002</b> , 105, 1650-5	4.8	907
924	Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. <i>Lancet, The</i> , <b>2016</b> , 388, 761-75	11.5	903
923	Effects of long-term vitamin E supplementation on cardiovascular events and cancer: a randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2005</b> , 293, 1338-47	7.4	878
922	Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial. <i>Circulation</i> , <b>2011</b> , 123, 2363-72	4.8	872
921	Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. <i>Lancet, The</i> , <b>2015</b> , 386, 266-73	11.5	871
920	Global burden of cardiovascular diseases: Part II: variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies. <i>Circulation</i> , <b>2001</b> , 104, 2855-64	4.8	840
919	Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. <i>American Heart Journal</i> , <b>2009</b> , 157, 132-40	1.3	781

918	Emerging epidemic of cardiovascular disease in developing countries. <i>Circulation</i> , <b>1998</b> , 97, 596-601	4.8	773
917	Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial. <i>Lancet, The</i> , <b>2010</b> , 376, 975-83	11.5	754
916	Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). <i>Lancet, The</i> , <b>2000</b> , 356, 279-84	11.5	748
915	Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 1238-51	18	717
914	Renal function as a predictor of outcome in a broad spectrum of patients with heart failure. <i>Circulation</i> , <b>2006</b> , 113, 671-8	4.8	694
913	Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 295, 1519-30	7.4	685
912	Predictors of mortality and morbidity in patients with chronic heart failure. <i>European Heart Journal</i> , <b>2006</b> , 27, 65-75	3.5	680
911	Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. <i>Circulation</i> , <b>2008</b> , 118, 2029-37	4.8	670
910	Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. <i>Lancet, The</i> , <b>2006</b> , 368, 647-58	11.5	668
909	Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. <i>Circulation</i> , <b>2004</b> , 110, 1202-8	4.8	667
908	n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. <i>New England Journal of Medicine</i> , <b>2012</b> , 367, 309-18	18	659
907	Red cell distribution width as a novel prognostic marker in heart failure: data from the CHARM Program and the Duke Databank. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 50, 40-7	3.8	630
906	Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. <i>Lancet, The</i> , <b>2011</b> , 378, 1231-43	11.5	627
905	Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence. <i>Annals of Internal Medicine</i> , <b>1999</b> , 131, 363-75	2.5	627
904	Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 45, 1832-9	3.8	625
903	Double-dose versus standard-dose clopidogrel and high-dose versus low-dose aspirin in individuals undergoing percutaneous coronary intervention for acute coronary syndromes (CURRENT-OASIS 7): a randomised factorial trial. <i>Lancet, The</i> , <b>2010</b> , 376, 1233-43	11.5	624
902	Cardiovascular sequelae of preeclampsia/eclampsia: a systematic review and meta-analyses. <i>American Heart Journal</i> , <b>2008</b> , 156, 918-30	1.3	617
901	Telmisartan to prevent recurrent stroke and cardiovascular events. <i>New England Journal of Medicine</i> , <b>2008</b> , 359, 1225-37	18	606

900	Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). <i>Circulation</i> , <b>2001</b> , 103, 919-25	4.8	606
899	Randomized Trial of Benznidazole for Chronic Chagas' Cardiomyopathy. <i>New England Journal of Medicine</i> , <b>2015</b> , 373, 1295-306	18	605
898	Impact of diabetes on long-term prognosis in patients with unstable angina and non-Q-wave myocardial infarction: results of the OASIS (Organization to Assess Strategies for Ischemic Syndromes) Registry. <i>Circulation</i> , <b>2000</b> , 102, 1014-9	4.8	598
897	The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 821-8	3.8	585
896	Newly identified events in the RE-LY trial. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 1875-6	18	584
895	Why do we need some large, simple randomized trials?. <i>Statistics in Medicine</i> , <b>1984</b> , 3, 409-22	0.5	584
894	Associations of fats and carbohydrate intake with cardiovascular disease and mortality in 18 countries from five continents (PURE): a prospective cohort study. <i>Lancet, The</i> , <b>2017</b> , 390, 2050-2062	11.5	583
893	Effect of ramipril on the incidence of diabetes. <i>New England Journal of Medicine</i> , <b>2006</b> , 355, 1551-62	18	583
892	Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 930-42	18	582
891	Early versus delayed invasive intervention in acute coronary syndromes. <i>New England Journal of Medicine</i> , <b>2009</b> , 360, 2165-75	18	578
890	Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes: observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. <i>Circulation</i> , <b>2003</b> , 108, 1682-7	4.8	578
889	Effects of physiologic pacing versus ventricular pacing on the risk of stroke and death due to cardiovascular causes. Canadian Trial of Physiologic Pacing Investigators. <i>New England Journal of Medicine</i> , <b>2000</b> , 342, 1385-91	18	577
888	Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. <i>Lancet, The</i> , <b>2008</b> , 372, 224-33	11.5	567
887	Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts. <i>Kidney International</i> , <b>2011</b> , 79, 1341-52	2.7	562
886	Urinary sodium and potassium excretion, mortality, and cardiovascular events. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 612-23	18	553
885	Prognostic importance of weight loss in chronic heart failure and the effect of treatment with angiotensin-converting-enzyme inhibitors: an observational study. <i>Lancet, The</i> , <b>2003</b> , 361, 1077-83	11.5	546
884	Risk factors for early myocardial infarction in South Asians compared with individuals in other countries. <i>JAMA - Journal of the American Medical Association</i> , <b>2007</b> , 297, 286-94	7.4	540
883	Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. <i>Circulation</i> , <b>2005</b> , 112, 3738-44	4.8	540

882	Multiancestry genome-wide association study of 520,000 subjects identifies 32 loci associated with stroke and stroke subtypes. <i>Nature Genetics</i> , <b>2018</b> , 50, 524-537	7	536
881	Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. <i>JAMA - Journal of the American Medical Association</i> , <b>2005</b> , 293, 2908-774	7.4	534
880	Aspirin in patients undergoing noncardiac surgery. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 1494-5038	3.8	525
879	Myocardial injury after noncardiac surgery: a large, international, prospective cohort study establishing diagnostic criteria, characteristics, predictors, and 30-day outcomes. <i>Anesthesiology</i> , <b>2014</b> , 120, 564-78	1.2	509
878	Cardiovascular risk and events in 17 low-, middle-, and high-income countries. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 818-27	18	499
877	Association of urinary sodium and potassium excretion with blood pressure. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 601-11	18	494
876	Off-pump or on-pump coronary-artery bypass grafting at 30 days. <i>New England Journal of Medicine</i> , <b>2012</b> , 366, 1489-97	18	494
875	The effect of physical activity on mortality and cardiovascular disease in 130 000 people from 17 high-income, middle-income, and low-income countries: the PURE study. <i>Lancet, The</i> , <b>2017</b> , 390, 2643-2654	11.5	492
874	Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. <i>European Heart Journal</i> , <b>2008</b> , 29, 932-40	3.5	487
873	Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2005</b> , 293, 437-46	7.4	468
872	Cholesterol Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 2021-31	18	440
871	Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. <i>Circulation</i> , <b>2001</b> , 104, 1615-21	4.8	439
870	Dronedarone in high-risk permanent atrial fibrillation. <i>New England Journal of Medicine</i> , <b>2011</b> , 365, 2268-76	4.8	438
869	Effects of CYP2C19 genotype on outcomes of clopidogrel treatment. <i>New England Journal of Medicine</i> , <b>2010</b> , 363, 1704-14	18	428
868	Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: an analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , <b>2008</b> , 29, 1377-85	3.5	419
867	Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2018</b> , 391, 219-229	11.5	414
866	Association of diet, exercise, and smoking modification with risk of early cardiovascular events after acute coronary syndromes. <i>Circulation</i> , <b>2010</b> , 121, 750-8	4.8	412
865	Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. <i>Circulation</i> , <b>2012</b> , 126, 343-8	4.8	409

864	Characteristics and short-term prognosis of perioperative myocardial infarction in patients undergoing noncardiac surgery: a cohort study. <i>Annals of Internal Medicine</i> , <b>2011</b> , 154, 523-8	2.5	409
863	Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 47, 1997-2004	3.8	406
862	Defining obesity cut points in a multiethnic population. <i>Circulation</i> , <b>2007</b> , 115, 2111-8	4.8	402
861	Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. <i>Circulation</i> , <b>2007</b> , 116, 1482-7	4.8	400
860	Randomized trial of primary PCI with or without routine manual thrombectomy. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 1389-98	18	396
859	The Prospective Urban Rural Epidemiology (PURE) study: examining the impact of societal influences on chronic noncommunicable diseases in low-, middle-, and high-income countries. <i>American Heart Journal</i> , <b>2009</b> , 158, 1-7.e1	1.3	396
858	Ramipril and the development of diabetes. <i>JAMA - Journal of the American Medical Association</i> , <b>2001</b> , 286, 1882-5	7.4	390
857	Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. <i>Circulation</i> , <b>2013</b> , 127, 634-40	4.8	387
856	Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. <i>Lancet, The</i> , <b>2006</b> , 368, 581-8	11.5	386
855	Blood-Pressure Lowering in Intermediate-Risk Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 2009-20	18	382
854	Dabigatran versus warfarin in patients with atrial fibrillation: an analysis of patients undergoing cardioversion. <i>Circulation</i> , <b>2011</b> , 123, 131-6	4.8	380
853	Urinary sodium and potassium excretion and risk of cardiovascular events. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 306, 2229-38	7.4	375
852	Interventions on prevention of postoperative atrial fibrillation in patients undergoing heart surgery: a meta-analysis. <i>Circulation</i> , <b>2002</b> , 106, 75-80	4.8	371
851	Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. <i>Lancet, The</i> , <b>2008</b> , 371, 1435-42	11.5	369
850	Reducing the Global Burden of Cardiovascular Disease, Part 1: The Epidemiology and Risk Factors. <i>Circulation Research</i> , <b>2017</b> , 121, 677-694	5.2	365
849	Excess of rare variants in genes identified by genome-wide association study of hypertriglyceridemia. <i>Nature Genetics</i> , <b>2010</b> , 42, 684-7	7	365
848	Diabetes mellitus, a predictor of morbidity and mortality in the Studies of Left Ventricular Dysfunction (SOLVD) Trials and Registry. <i>American Journal of Cardiology</i> , <b>1996</b> , 77, 1017-20	0.7	362
847	Overcoming the limitations of current meta-analysis of randomised controlled trials. <i>Lancet, The</i> , <b>1998</b> , 351, 47-52	11.5	354

846	Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 50, 2156-61	3.8	354
845	ACC/AHA Guidelines for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1991 Guidelines for Coronary Artery Bypass Graft Surgery). American College of Cardiology/American Heart Association. <i>Journal of the American College of Cardiology</i> , <b>1999</b> , 34, 1262-347	3.8	347
844	Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. <i>Lancet, The</i> , <b>2000</b> , 355, 1936-42	11.5	343
843	Modifiable risk factors, cardiovascular disease, and mortality in 155 722 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. <i>Lancet, The</i> , <b>2020</b> , 395, 795-808	11.5	342
842	Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. <i>Stroke</i> , <b>2012</b> , 43, 1511-7	1.8	333
841	Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke: a subgroup analysis of the RE-LY trial. <i>Lancet Neurology, The</i> , <b>2010</b> , 9, 1157-1163	5.3	329
840	Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy. <i>Hypertension</i> , <b>2001</b> , 38, E28-32	2.4	329
839	ACC/AHA guidelines for coronary artery bypass graft surgery: executive summary and recommendations : A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to revise the 1991 guidelines for coronary artery bypass graft surgery). <i>Circulation</i> , <b>1999</b> , 100, 1464-80	4.8	319
838	Effects of off-pump and on-pump coronary-artery bypass grafting at 1 year. <i>New England Journal of Medicine</i> , <b>2013</b> , 368, 1179-88	18	318
837	Cumulating evidence from randomized trials: utilizing sequential monitoring boundaries for cumulative meta-analysis. <i>Contemporary Clinical Trials</i> , <b>1997</b> , 18, 580-93; discussion 661-6		308
836	Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial. <i>Circulation</i> , <b>2012</b> , 125, 669-76	4.8	306
835	Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICRO-HOPE substudy. <i>Diabetes Care</i> , <b>2002</b> , 25, 1919-27	3.9	306
834	Impact of right ventricular involvement on mortality and morbidity in patients with inferior myocardial infarction. <i>Journal of the American College of Cardiology</i> , <b>2001</b> , 37, 37-43	3.8	306
833	Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications. <i>European Heart Journal</i> , <b>2010</b> , 31, 642-8	3.5	302
832	Dietary patterns and the risk of acute myocardial infarction in 52 countries: results of the INTERHEART study. <i>Circulation</i> , <b>2008</b> , 118, 1929-37	4.8	301
831	Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. <i>Lancet, The</i> , <b>2019</b> , 393, 407-415	11.5	300
830	Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 60, 2490-9	3.8	296
829	Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-term Anticoagulation Therapy) trial analysis. <i>Circulation</i> , <b>2014</b> , 129, 961-70	4.8	293



828	Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. <i>Circulation</i> , <b>2012</b> , 125, 1605-16	4.8	291
827	Variations between countries in invasive cardiac procedures and outcomes in patients with suspected unstable angina or myocardial infarction without initial ST elevation. OASIS (Organisation to Assess Strategies for Ischaemic Syndromes) Registry Investigators. <i>Lancet, The</i> , <b>1998</b> , 352, 507-14	11.5	291
826	Oral anticoagulant and antiplatelet therapy and peripheral arterial disease. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 217-27	18	287
825	Fruit, vegetable, and legume intake, and cardiovascular disease and deaths in 18 countries (PURE): a prospective cohort study. <i>Lancet, The</i> , <b>2017</b> , 390, 2037-2049	11.5	285
824	Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. <i>Lancet, The</i> , <b>2003</b> , 361, 1843-8	11.5	284
823	Mortality and morbidity reduction with Candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. <i>Circulation</i> , <b>2004</b> , 110, 2618-26	4.8	282
822	Two decades of progress in preventing vascular disease. <i>Lancet, The</i> , <b>2002</b> , 360, 2-3	11.5	281
821	Baseline quality of life as a predictor of mortality and hospitalization in 5,025 patients with congestive heart failure. SOLVD Investigations. Studies of Left Ventricular Dysfunction Investigators. <i>American Journal of Cardiology</i> , <b>1996</b> , 78, 890-5	0.7	280
820	Characteristics, complications, and gaps in evidence-based interventions in rheumatic heart disease: the Global Rheumatic Heart Disease Registry (the REMEDY study). <i>European Heart Journal</i> , <b>2015</b> , 36, 1115-22a	3.5	278
819	Principles for national and regional guidelines on cardiovascular disease prevention: a scientific statement from the World Heart and Stroke Forum. <i>Circulation</i> , <b>2004</b> , 109, 3112-21	4.8	274
818	The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. <i>Lancet, The</i> , <b>2016</b> , 387, 2302-2311	11.5	272
817	Body mass index and prognosis in patients with chronic heart failure: insights from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>Circulation</i> , <b>2007</b> , 116, 627-36	4.8	264
816	Prognostic significance of plasma norepinephrine in patients with asymptomatic left ventricular dysfunction. SOLVD Investigators. <i>Circulation</i> , <b>1996</b> , 94, 690-7	4.8	263
815	Effect of amiodarone on mortality after myocardial infarction: a double-blind, placebo-controlled, pilot study. <i>Journal of the American College of Cardiology</i> , <b>1992</b> , 20, 1056-62	3.8	260
814	Food Consumption and its Impact on Cardiovascular Disease: Importance of Solutions Focused on the Globalized Food System: A Report From the Workshop Convened by the World Heart Federation. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 66, 1590-1614	3.8	255
813	Prognostic impact of body weight and abdominal obesity in women and men with cardiovascular disease. <i>American Heart Journal</i> , <b>2005</b> , 149, 54-60	1.3	252
812	Variations in cause and management of atrial fibrillation in a prospective registry of 15,400 emergency department patients in 46 countries: the RE-LY Atrial Fibrillation Registry. <i>Circulation</i> , <b>2014</b> , 129, 1568-76	4.8	250
811	Early and late effects of clopidogrel in patients with acute coronary syndromes. <i>Circulation</i> , <b>2003</b> , 107, 966-72	4.8	250

810	Liver function abnormalities and outcome in patients with chronic heart failure: data from the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) program. <i>European Journal of Heart Failure</i> , <b>2009</b> , 11, 170-7	3.1	247
809	Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. <i>Lancet Neurology</i> , <b>2008</b> , 7, 875-84	5.3	247
808	Effects of exercise training in patients with heart failure: the Exercise Rehabilitation Trial (EXERT). <i>American Heart Journal</i> , <b>2002</b> , 144, 23-30	1.3	246
807	Risk factors associated with myocardial infarction in Africa: the INTERHEART Africa study. <i>Circulation</i> , <b>2005</b> , 112, 3554-61	4.8	237
806	Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta-analysis. <i>European Journal of Heart Failure</i> , <b>2005</b> , 7, 1133-44	3.1	235
805	Does PTCA in acute myocardial infarction affect mortality and reinfarction rates? A quantitative overview (meta-analysis) of the randomized clinical trials. <i>Circulation</i> , <b>1995</b> , 91, 476-85	4.8	230
804	Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. <i>Circulation</i> , <b>2003</b> , 108, 420-5	4.8	227
803	PCSK9 genetic variants and risk of type 2 diabetes: a mendelian randomisation study. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 97-105	4.9	225
802	Candesartan in heart failure--assessment of reduction in mortality and morbidity (CHARM): rationale and design. ChARM-Programme Investigators. <i>Journal of Cardiac Failure</i> , <b>1999</b> , 5, 276-82	1	224
801	Management and outcomes of major bleeding during treatment with dabigatran or warfarin. <i>Circulation</i> , <b>2013</b> , 128, 2325-32	4.8	222
800	Clonidine in patients undergoing noncardiac surgery. <i>New England Journal of Medicine</i> , <b>2014</b> , 370, 1504-13		219
799	Dabigatran versus warfarin: effects on ischemic and hemorrhagic strokes and bleeding in Asians and non-Asians with atrial fibrillation. <i>Stroke</i> , <b>2013</b> , 44, 1891-6	1.8	219
798	Reliability, validity, and responsiveness of the six-minute walk test in patients with heart failure. <i>American Heart Journal</i> , <b>2001</b> , 142, 698-703	1.3	219
797	Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. <i>Lancet</i> , <b>2020</b> , 395, 785-794	11.5	218
796	Update of effects of calcium antagonists in myocardial infarction or angina in light of the second Danish Verapamil Infarction Trial (DAVIT-II) and other recent studies. <i>American Journal of Cardiology</i> , <b>1991</b> , 67, 1295-7	0.7	217
795	Risk factors, atherosclerosis, and cardiovascular disease among Aboriginal people in Canada: the Study of Health Assessment and Risk Evaluation in Aboriginal Peoples (SHARE-AP). <i>Lancet</i> , <b>2001</b> , 358, 1147-53	11.5	215
794	Differences in the management and prognosis of women and men who suffer from acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 46, 1845-51	3.8	212
793	Availability and affordability of cardiovascular disease medicines and their effect on use in high-income, middle-income, and low-income countries: an analysis of the PURE study data. <i>Lancet</i> , <b>2016</b> , 387, 61-9	11.5	211

792	The DREAM trial [Authors' reply]. <i>Lancet, The</i> , <b>2006</b> , 368, 2050-2051	11.5	207
791	Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study. <i>Circulation</i> , <b>2013</b> , 128, 2192-201	4.8	206
790	Risk factors for acute myocardial infarction in Latin America: the INTERHEART Latin American study. <i>Circulation</i> , <b>2007</b> , 115, 1067-74	4.8	206
789	Patient and healthcare provider barriers to hypertension awareness, treatment and follow up: a systematic review and meta-analysis of qualitative and quantitative studies. <i>PLoS ONE</i> , <b>2014</b> , 9, e84238	1.2	205
788	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2018</b> , 391, 205-218	11.5	204
787	Five-Year Outcomes after Off-Pump or On-Pump Coronary-Artery Bypass Grafting. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 2359-2368	18	203
786	Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes undergoing percutaneous coronary intervention: results from the OASIS-5 trial. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 50, 1742-51	3.8	203
785	Effect of candesartan on cause-specific mortality in heart failure patients: the Candesartan in Heart failure Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>Circulation</i> , <b>2004</b> , 110, 2180-3	4.8	203
784	Risk factors for acute myocardial infarction in Indians: a case-control study. <i>Lancet, The</i> , <b>1996</b> , 348, 358-61	11.5	203
783	Availability, affordability, and consumption of fruits and vegetables in 18 countries across income levels: findings from the Prospective Urban Rural Epidemiology (PURE) study. <i>The Lancet Global Health</i> , <b>2016</b> , 4, e695-703	4	199
782	Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , <b>2016</b> , 374, 2032-43	18	199
781	Blood-pressure reduction and cardiovascular risk in HOPE study. <i>Lancet, The</i> , <b>2001</b> , 358, 2130-1	11.5	195
780	Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program. <i>Circulation</i> , <b>2006</b> , 113, 986-94	4.8	194
779	Irbesartan in patients with atrial fibrillation. <i>New England Journal of Medicine</i> , <b>2011</b> , 364, 928-38	18	193
778	Methylprednisolone in patients undergoing cardiopulmonary bypass (SIRS): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , <b>2015</b> , 386, 1243-1253	11.5	192
777	Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. <i>Circulation</i> , <b>2002</b> , 106, 1622-6	4.8	192
776	Effect of intravenous streptokinase on acute myocardial infarction: pooled results from randomized trials. <i>New England Journal of Medicine</i> , <b>1982</b> , 307, 1180-2	18	192
775	Albuminuria in chronic heart failure: prevalence and prognostic importance. <i>Lancet, The</i> , <b>2009</b> , 374, 543-50	11.5	191

774	Association of dairy intake with cardiovascular disease and mortality in 21 countries from five continents (PURE): a prospective cohort study. <i>Lancet, The</i> , <b>2018</b> , 392, 2288-2297	11.5	191
773	Prevalence of a healthy lifestyle among individuals with cardiovascular disease in high-, middle- and low-income countries: The Prospective Urban Rural Epidemiology (PURE) study. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 309, 1613-21	7.4	190
772	Changes in albuminuria predict mortality and morbidity in patients with vascular disease. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2011</b> , 22, 1353-64	3.2	190
771	Relation of neurohumoral activation to clinical variables and degree of ventricular dysfunction: a report from the Registry of Studies of Left Ventricular Dysfunction. SOLVD Investigators. <i>Journal of the American College of Cardiology</i> , <b>1994</b> , 23, 1410-20	3.8	190
770	Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. <i>American Journal of Human Genetics</i> , <b>2012</b> , 91, 823-38	2.5	189
769	Sex differences in clinical characteristics and prognosis in a broad spectrum of patients with heart failure: results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>Circulation</i> , <b>2007</b> , 115, 3111-20	4.8	188
768	Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. <i>Lancet, The</i> , <b>2002</b> , 360, 1037-43	11.5	188
767	Increased winter mortality from acute myocardial infarction and stroke: the effect of age. <i>Journal of the American College of Cardiology</i> , <b>1999</b> , 33, 1916-9	3.8	188
766	Effects of candesartan on the development of a new diagnosis of diabetes mellitus in patients with heart failure. <i>Circulation</i> , <b>2005</b> , 112, 48-53	4.8	185
765	Is a pre-operative brain natriuretic peptide or N-terminal pro-B-type natriuretic peptide measurement an independent predictor of adverse cardiovascular outcomes within 30 days of noncardiac surgery? A systematic review and meta-analysis of observational studies. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, 1599-606	3.8	184
764	Cardiovascular outcomes with atrial-based pacing compared with ventricular pacing: meta-analysis of randomized trials, using individual patient data. <i>Circulation</i> , <b>2006</b> , 114, 11-7	4.8	182
763	Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study. <i>Circulation</i> , <b>2003</b> , 107, 1284-90	4.8	176
762	Genetic determinants of dabigatran plasma levels and their relation to bleeding. <i>Circulation</i> , <b>2013</b> , 127, 1404-12	4.8	174
761	Major Adverse Limb Events and Mortality in Patients With Peripheral Artery Disease: The COMPASS Trial. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 71, 2306-2315	3.8	173
760	Strengths and limitations of meta-analysis: larger studies may be more reliable. <i>Contemporary Clinical Trials</i> , <b>1997</b> , 18, 568-79; discussion 661-6		173
759	Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials. <i>Lancet, The</i> , <b>2017</b> , 389, 2226-2237	11.5	171
758	WHO study on Prevention of REcurrences of Myocardial Infarction and Stroke (WHO-PREMISE). <i>Bulletin of the World Health Organization</i> , <b>2005</b> , 83, 820-9	2	168
757	Prednisolone and Mycobacterium indicus pranii in tuberculous pericarditis. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1121-30	18	167

756	Does hypoglycaemia increase the risk of cardiovascular events? A report from the ORIGIN trial. <i>European Heart Journal</i> , <b>2013</b> , 34, 3137-44	3.5	167
755	The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study. <i>Circulation</i> , <b>2013</b> , 128, 237-43	4.8	166
754	Level of systolic blood pressure within the normal range and risk of recurrent stroke. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 306, 2137-44	7.4	161
753	Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 1230-1239	3.1	159
752	Urinary sodium excretion, blood pressure, cardiovascular disease, and mortality: a community-level prospective epidemiological cohort study. <i>Lancet, The</i> , <b>2018</b> , 392, 496-506	11.5	159
751	Stemming the global tsunami of cardiovascular disease. <i>Lancet, The</i> , <b>2011</b> , 377, 529-32	11.5	159
750	Thrombus Aspiration in ST-Segment-Elevation Myocardial Infarction: An Individual Patient Meta-Analysis: Thrombectomy Trialists Collaboration. <i>Circulation</i> , <b>2017</b> , 135, 143-152	4.8	157
749	Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. <i>Annals of Internal Medicine</i> , <b>2011</b> , 155, 660-7, W204	2.5	157
748	Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study. <i>Circulation</i> , <b>2001</b> , 104, 522-6	4.8	157
747	Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation: a cohort study. <i>Lancet, The</i> , <b>2016</b> , 388, 1161-9	11.5	157
746	Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. <i>Journal of the American College of Cardiology</i> , <b>2001</b> , 38, 806-13	3.8	155
745	Socioeconomic status and risk of cardiovascular disease in 20 low-income, middle-income, and high-income countries: the Prospective Urban Rural Epidemiologic (PURE) study. <i>The Lancet Global Health</i> , <b>2019</b> , 7, e748-e760	4	153
744	Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. <i>European Heart Journal</i> , <b>2011</b> , 32, 581-9	3.5	153
743	Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: the BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT). <i>American Heart Journal</i> , <b>2008</b> , 156, 37-43	1.3	153
742	Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension. <i>Circulation</i> , <b>2005</b> , 112, 1339-46	4.8	153
741	Global mortality variations in patients with heart failure: results from the International Congestive Heart Failure (INTER-CHF) prospective cohort study. <i>The Lancet Global Health</i> , <b>2017</b> , 5, e665-e672	4	148
740	C-reactive protein as a screening test for cardiovascular risk in a multiethnic population. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2004</b> , 24, 1509-15	2.7	148
739	Metabolic syndrome and risk of acute myocardial infarction a case-control study of 26,903 subjects from 52 countries. <i>Journal of the American College of Cardiology</i> , <b>2010</b> , 55, 2390-8	3.8	146

738	Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PROFESS). <i>Cerebrovascular Diseases</i> , <b>2007</b> , 23, 368-80	0.8	145
737	Canadian Trial of Physiological Pacing: Effects of physiological pacing during long-term follow-up. <i>Circulation</i> , <b>2004</b> , 109, 357-62	4.8	145
736	Dabigatran in patients with myocardial injury after non-cardiac surgery (MANAGE): an international, randomised, placebo-controlled trial. <i>Lancet, The</i> , <b>2018</b> , 391, 2325-2334	11.5	142
735	Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies. <i>Lancet Neurology, The</i> , <b>2011</b> , 10, 43-53	5.3	142
734	Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONGoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. <i>Circulation</i> , <b>2010</b> , 121, 1439-46	4.8	142
733	Effects of exercise training in patients with congestive heart failure: a critical review. <i>Journal of the American College of Cardiology</i> , <b>1995</b> , 25, 789-96	3.8	142
732	Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 33-40	3.1	141
731	Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. <i>Lancet, The</i> , <b>2016</b> , 387, 127-35	11.5	140
730	Lipid profile, plasma apolipoproteins, and risk of a first myocardial infarction among Asians: an analysis from the INTERHEART Study. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 53, 244-53	3.8	140
729	Dabigatran and warfarin in vitamin K antagonist-naive and -experienced cohorts with atrial fibrillation. <i>Circulation</i> , <b>2010</b> , 122, 2246-53	4.8	138
728	Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 83-91	3.1	138
727	Clinical Outcomes in 3343 Children and Adults With Rheumatic Heart Disease From 14 Low- and Middle-Income Countries: Two-Year Follow-Up of the Global Rheumatic Heart Disease Registry (the REMEDY Study). <i>Circulation</i> , <b>2016</b> , 134, 1456-1466	4.8	136
726	Weight loss and mortality risk in patients with chronic heart failure in the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , <b>2008</b> , 29, 2641-50	3.5	135
725	Angiotensin-converting enzyme inhibitor as a risk factor for the development of anemia, and the impact of incident anemia on mortality in patients with left ventricular dysfunction. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 45, 391-9	3.8	135
724	Homocysteine and coronary heart disease: meta-analysis of MTHFR case-control studies, avoiding publication bias. <i>PLoS Medicine</i> , <b>2012</b> , 9, e1001177	3.6	135
723	Reducing the Global Burden of Cardiovascular Disease, Part 2: Prevention and Treatment of Cardiovascular Disease. <i>Circulation Research</i> , <b>2017</b> , 121, 695-710	5.2	134
722	The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. <i>European Heart Journal</i> , <b>2013</b> , 34, 170-6	3.5	134
721	Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial. <i>Lancet Neurology, The</i> , <b>2012</b> , 11, 225-31	5.3	132

720	Changes in Renal Function in Patients With Atrial Fibrillation: An Analysis From the RE-LY Trial. <i>Journal of the American College of Cardiology</i> , <b>2015</b> , 65, 2481-93	3.8	130
719	Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2010</b> , 304, 1339-49	7.4	130
718	Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). <i>Stroke</i> , <b>2008</b> , 39, 1482-6	1.8	130
717	Quality of life among 5,025 patients with left ventricular dysfunction randomized between placebo and enalapril: the Studies of Left Ventricular Dysfunction. The SOLVD Investigators. <i>Journal of the American College of Cardiology</i> , <b>1994</b> , 23, 393-400	3.8	130
716	Incidence and predictors of hyperkalemia in patients with heart failure: an analysis of the CHARM Program. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 50, 1959-66	3.8	129
715	Clinical effects of early angiotensin-converting enzyme inhibitor treatment for acute myocardial infarction are similar in the presence and absence of aspirin: systematic overview of individual data from 96,712 randomized patients. Angiotensin-converting Enzyme Inhibitor Myocardial Infarction Collaborative Group. <i>Journal of the American College of Cardiology</i> , <b>2000</b> , 35, 1221-7	3.8	129
714	Reference ranges of handgrip strength from 125,462 healthy adults in 21 countries: a prospective urban rural epidemiologic (PURE) study. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , <b>2016</b> , 7, 535-546	1.9	129
713	Saturated Fats and Health: A Reassessment and Proposal for Food-Based Recommendations: JACC State-of-the-Art Review. <i>Journal of the American College of Cardiology</i> , <b>2020</b> , 76, 844-857	3.8	128
712	Ethnic variation in adiponectin and leptin levels and their association with adiposity and insulin resistance. <i>Diabetes Care</i> , <b>2010</b> , 33, 1629-34	3.9	128
711	From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis. <i>American Journal of Cardiology</i> , <b>2002</b> , 89, 18A-25A; discussion 25A-26A	0.7	127
710	Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination With Ramipril Global Endpoint Trial). <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 74-83	3.8	126
709	Relationship of current and past smoking to mortality and morbidity in patients with left ventricular dysfunction. <i>Journal of the American College of Cardiology</i> , <b>2001</b> , 37, 1677-82	3.8	126
708	Clinical effects of anticoagulant therapy in suspected acute myocardial infarction: systematic overview of randomised trials. <i>BMJ: British Medical Journal</i> , <b>1996</b> , 313, 652-9		126
707	Association of dietary nutrients with blood lipids and blood pressure in 18 countries: a cross-sectional analysis from the PURE study. <i>Lancet Diabetes and Endocrinology</i> , <b>2017</b> , 5, 774-787	4.9	125
706	Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET). <i>Circulation</i> , <b>2011</b> , 124, 1727-36	4.8	121
705	Improving clinical outcomes by reducing bleeding in patients with non-ST-elevation acute coronary syndromes. <i>European Heart Journal</i> , <b>2009</b> , 30, 655-61	3.5	121
704	The polypill in the prevention of cardiovascular diseases: key concepts, current status, challenges, and future directions. <i>Circulation</i> , <b>2010</b> , 122, 2078-88	4.8	120
703	Specific barriers to the conduct of randomized trials. <i>Clinical Trials</i> , <b>2008</b> , 5, 40-8	0.6	120

702	Kidney function after off-pump or on-pump coronary artery bypass graft surgery: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 311, 2191-8	7.4	119
701	Association of heart rate and outcomes in a broad spectrum of patients with chronic heart failure: results from the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and morbidity) program. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 1785-95	3.8	119
700	Multiple infections and subsequent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study. <i>Circulation</i> , <b>2003</b> , 107, 251-7	4.8	119
699	Glucose-insulin-potassium therapy in patients with ST-segment elevation myocardial infarction. <i>JAMA - Journal of the American Medical Association</i> , <b>2007</b> , 298, 2399-405	7.4	118
698	Revascularization for unprotected left main stem coronary artery stenosis stenting or surgery. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 51, 885-92	3.8	117
697	Alcohol consumption and cardiovascular disease, cancer, injury, admission to hospital, and mortality: a prospective cohort study. <i>Lancet, The</i> , <b>2015</b> , 386, 1945-1954	11.5	116
696	Effect of telmisartan on renal outcomes: a randomized trial. <i>Annals of Internal Medicine</i> , <b>2009</b> , 151, 1-10, W1-2	2.5	116
695	Incidence, predictive factors, and prognostic significance of supraventricular tachyarrhythmias in congestive heart failure. <i>Chest</i> , <b>2000</b> , 118, 914-22	1.2	116
694	Comparison of Dabigatran and Warfarin in Patients With Atrial Fibrillation and Valvular Heart Disease: The RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulant Therapy). <i>Circulation</i> , <b>2016</b> , 134, 589-98	4.8	116
693	Effect of vasodilators on survival in chronic congestive heart failure. <i>American Journal of Cardiology</i> , <b>1985</b> , 55, 1110-3	0.7	115
692	Relationship between healthy diet and risk of cardiovascular disease among patients on drug therapies for secondary prevention: a prospective cohort study of 31 546 high-risk individuals from 40 countries. <i>Circulation</i> , <b>2012</b> , 126, 2705-12	4.8	114
691	Environmental and societal influences acting on cardiovascular risk factors and disease at a population level: a review. <i>International Journal of Epidemiology</i> , <b>2009</b> , 38, 1580-94	1.9	113
690	A multivariate model for predicting mortality in patients with heart failure and systolic dysfunction. <i>American Journal of Medicine</i> , <b>2004</b> , 116, 300-4	0.6	113
689	Lipoprotein(a) Levels and the Risk of Myocardial Infarction Among 7 Ethnic Groups. <i>Circulation</i> , <b>2019</b> , 139, 1472-1482	4.8	112
688	Early cerebral small vessel disease and brain volume, cognition, and gait. <i>Annals of Neurology</i> , <b>2015</b> , 77, 251-61	2.6	110
687	Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2003</b> , 14, 641-7	3.2	110
686	Indications for coronary artery bypass surgery and percutaneous coronary intervention in chronic stable angina: review of the evidence and methodological considerations. <i>Circulation</i> , <b>2003</b> , 108, 2439-45	4.8	109
685	Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. <i>Circulation</i> , <b>2005</b> , 112, 3855-67	4.8	109



684	Adipocyte hypertrophy, fatty liver and metabolic risk factors in South Asians: the Molecular Study of Health and Risk in Ethnic Groups (mol-SHARE). <i>PLoS ONE</i> , <b>2011</b> , 6, e22112	1.2	109
683	Variation in warfarin dose adjustment practice is responsible for differences in the quality of anticoagulation control between centers and countries: an analysis of patients receiving warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. <i>Circulation</i> , <b>2012</b> , 126, 2222-2231	4.8	108
682	Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. <i>JAMA - Journal of the American Medical Association</i> , <b>2005</b> , 293, 427-35	7.4	106
681	Variations in Diabetes Prevalence in Low-, Middle-, and High-Income Countries: Results From the Prospective Urban and Rural Epidemiological Study. <i>Diabetes Care</i> , <b>2016</b> , 39, 780-7	3.9	104
680	Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. <i>Circulation</i> , <b>2011</b> , 123, 1098-107	4.8	104
679	Sodium intake and cardiovascular health. <i>Circulation Research</i> , <b>2015</b> , 116, 1046-57	5.2	102
678	Effects of aspirin dose on ischaemic events and bleeding after percutaneous coronary intervention: insights from the PCI-CURE study. <i>European Heart Journal</i> , <b>2009</b> , 30, 900-7	3.5	102
677	Polygenic determinants of severe hypertriglyceridemia. <i>Human Molecular Genetics</i> , <b>2008</b> , 17, 2894-9	1.1	101
676	Pharmacological blood pressure lowering for primary and secondary prevention of cardiovascular disease across different levels of blood pressure: an individual participant-level data meta-analysis. <i>Lancet, The</i> , <b>2021</b> , 397, 1625-1636	11.5	101
675	Differential clinical outcomes associated with hypoglycemia and hyperglycemia in acute myocardial infarction. <i>Circulation</i> , <b>2009</b> , 120, 2429-37	4.8	99
674	Accelerated surgery versus standard care in hip fracture (HIP ATTACK): an international, randomised, controlled trial. <i>Lancet, The</i> , <b>2020</b> , 395, 698-708	11.5	98
673	Rationale, Design and Baseline Characteristics of Participants in the Cardiovascular Outcomes for People Using Anticoagulation Strategies (COMPASS) Trial. <i>Canadian Journal of Cardiology</i> , <b>2017</b> , 33, 1027-31	10.35	97
672	Influence of previous heart failure hospitalization on cardiovascular events in patients with reduced and preserved ejection fraction. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 590-5	1.7	97
671	Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. <i>Annals of Internal Medicine</i> , <b>2011</b> , 155, 579-86	2.5	97
670	Randomized trial of candesartan cilexetil in the treatment of patients with congestive heart failure and a history of intolerance to angiotensin-converting enzyme inhibitors. <i>American Heart Journal</i> , <b>2000</b> , 139, 609-17	1.3	97
669	Randomized, blinded trial comparing fondaparinux with unfractionated heparin in patients undergoing contemporary percutaneous coronary intervention: Arixtra Study in Percutaneous Coronary Intervention: a Randomized Evaluation (ASPIRE) Pilot Trial. <i>Circulation</i> , <b>2005</b> , 111, 1390-7	4.8	96
668	Comprehensive analysis of genomic variation in the LPA locus and its relationship to plasma lipoprotein(a) in South Asians, Chinese, and European Caucasians. <i>Circulation: Cardiovascular Genetics</i> , <b>2010</b> , 3, 39-46		95
667	The World Heart Federation's vision for worldwide cardiovascular disease prevention. <i>Lancet, The</i> , <b>2015</b> , 386, 399-402	11.5	94

666	Pathology of Peripheral Artery Disease in Patients With Critical Limb Ischemia. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 2152-2163	3.8	94
665	Development and evaluation of cultural food frequency questionnaires for South Asians, Chinese, and Europeans in North America. <i>Journal of the American Dietetic Association</i> , <b>2003</b> , 103, 1178-84		94
664	Clinical characteristics of patients in studies of left ventricular dysfunction (SOLVD). <i>American Journal of Cardiology</i> , <b>1992</b> , 70, 894-900	0.7	94
663	The Relationship Between Trimethylamine-N-Oxide and Prevalent Cardiovascular Disease in a Multiethnic Population Living in Canada. <i>Canadian Journal of Cardiology</i> , <b>2015</b> , 31, 1189-94	1.3	93
662	Days alive and out of hospital and the patient journey in patients with heart failure: Insights from the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) program. <i>American Heart Journal</i> , <b>2011</b> , 162, 900-6	1.3	93
661	Cognitive impairment and risk of cardiovascular events and mortality. <i>European Heart Journal</i> , <b>2012</b> , 33, 1777-86	3.5	92
660	Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation. <i>Journal of the American College of Cardiology</i> , <b>2005</b> , 45, 838-45	3.8	92
659	Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 1966-1976	3.8	91
658	Effect of long-term enalapril therapy on neurohormones in patients with left ventricular dysfunction. SOLVD Investigators. <i>American Journal of Cardiology</i> , <b>1995</b> , 75, 1151-7	0.7	91
657	Availability and affordability of blood pressure-lowering medicines and the effect on blood pressure control in high-income, middle-income, and low-income countries: an analysis of the PURE study data. <i>Lancet Public Health</i> , <b>2017</b> , 2, e411-e419	6.8	90
656	Parental history and myocardial infarction risk across the world: the INTERHEART Study. <i>Journal of the American College of Cardiology</i> , <b>2011</b> , 57, 619-27	3.8	90
655	Relationship of dose of background angiotensin-converting enzyme inhibitor to the benefits of candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. <i>American Heart Journal</i> , <b>2006</b> , 151, 985-91	1.3	90
654	INTER-HEART: A global study of risk factors for acute myocardial infarction. <i>American Heart Journal</i> , <b>2001</b> , 141, 711-21	1.3	90
653	Long-term oral anticoagulant therapy in patients with unstable angina or suspected non-Q-wave myocardial infarction: organization to assess strategies for ischemic syndromes (OASIS) pilot study results. <i>Circulation</i> , <b>1998</b> , 98, 1064-70	4.8	90
652	Patterns of alcohol consumption and myocardial infarction risk: observations from 52 countries in the INTERHEART case-control study. <i>Circulation</i> , <b>2014</b> , 130, 390-8	4.8	89
651	Physical activity levels, ownership of goods promoting sedentary behaviour and risk of myocardial infarction: results of the INTERHEART study. <i>European Heart Journal</i> , <b>2012</b> , 33, 452-66	3.5	89
650	Carotid Intima-Media Thickness Progression as Surrogate Marker for Cardiovascular Risk: Meta-Analysis of 119 Clinical Trials Involving 100 667 Patients. <i>Circulation</i> , <b>2020</b> , 142, 621-642	4.8	88
649	Prospective Urban Rural Epidemiology (PURE) study: Baseline characteristics of the household sample and comparative analyses with national data in 17 countries. <i>American Heart Journal</i> , <b>2013</b> , 166, 636-646.e4	1.3	87

648	Why are we failing to implement effective therapies in cardiovascular disease?. <i>European Heart Journal</i> , <b>2013</b> , 34, 1262-9	3.5	87
647	Relationship of activated partial thromboplastin time to coronary events and bleeding in patients with acute coronary syndromes who receive heparin. <i>Circulation</i> , <b>2003</b> , 107, 2884-8	4.8	86
646	Prognostic value of prolonged ventricular repolarization following myocardial infarction: the BHAT experience. The BHAT Study Group. <i>Journal of Clinical Epidemiology</i> , <b>1990</b> , 43, 167-72	1.6	86
645	The relationship between estimated sodium and potassium excretion and subsequent renal outcomes. <i>Kidney International</i> , <b>2014</b> , 86, 1205-12	2.7	85
644	Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , <b>2013</b> , 165, 17-24	0.8	84
643	Perioperative aspirin and clonidine and risk of acute kidney injury: a randomized clinical trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2014</b> , 312, 2254-64	7.4	84
642	Chronic pain syndromes after ischemic stroke: PRoFESS trial. <i>Stroke</i> , <b>2013</b> , 44, 1238-43	1.8	84
641	Evaluating the benefit of event adjudication of cardiovascular outcomes in large simple RCTs. <i>Clinical Trials</i> , <b>2009</b> , 6, 239-51	0.6	84
640	Effects of vitamin E on cardiovascular outcomes in people with mild-to-moderate renal insufficiency: results of the HOPE study. <i>Kidney International</i> , <b>2004</b> , 65, 1375-80	2.7	84
639	Mendelian randomization analysis supports the causal role of dysglycaemia and diabetes in the risk of coronary artery disease. <i>European Heart Journal</i> , <b>2015</b> , 36, 1454-62	3.5	83
638	Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease. <i>Circulation</i> , <b>2009</b> , 120, 1380-9	4.8	83
637	Resequencing genomic DNA of patients with severe hypertriglyceridemia (MIM 144650). <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2007</b> , 27, 2450-5	2.7	83
636	Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study. <i>American Heart Journal</i> , <b>2007</b> , 154, 448-53	1.3	83
635	Relationship between pacemaker dependency and the effect of pacing mode on cardiovascular outcomes. <i>Circulation</i> , <b>2001</b> , 103, 3081-5	4.8	83
634	Current status of safety and efficacy of calcium channel blockers in cardiovascular diseases: a critical analysis based on 100 studies. <i>Progress in Cardiovascular Diseases</i> , <b>2000</b> , 43, 171-96	1.9	82
633	Association of estimated sleep duration and naps with mortality and cardiovascular events: a study of 116 632 people from 21 countries. <i>European Heart Journal</i> , <b>2019</b> , 40, 1620-1629	3.5	82
632	Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus. <i>JAMA Internal Medicine</i> , <b>2013</b> , 173, 1682-92	3.2	81
631	Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial. <i>Journal of the American College of Cardiology</i> , <b>2004</b> , 43, 2200-6	3.8	81

630	Adherence to medication according to sex and age in the CHARM programme. <i>European Journal of Heart Failure</i> , <b>2009</b> , 11, 1092-8	3.1	80
629	A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial. <i>Lancet, The</i> , <b>2019</b> , 394, 1231-1242	11.5	79
628	Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease. <i>Journal of Stroke and Cerebrovascular Diseases</i> , <b>2012</b> , 21, 429-35	0.8	79
627	Cognitive function and anticoagulation control in patients with atrial fibrillation. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2010</b> , 3, 277-83	1.3	79
626	Physical Activity and Anger or Emotional Upset as Triggers of Acute Myocardial Infarction: The INTERHEART Study. <i>Circulation</i> , <b>2016</b> , 134, 1059-1067	4.8	79
625	Randomized clinical trials--removing unnecessary obstacles. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 1061-5	18	78
624	Randomized trial of aspirin and clopidogrel versus aspirin alone for the prevention of coronary artery bypass graft occlusion: the Preoperative Aspirin and Postoperative Antiplatelets in Coronary Artery Bypass Grafting study. <i>American Heart Journal</i> , <b>2010</b> , 160, 1178-84	1.3	78
623	A polygenic basis for four classical Fredrickson hyperlipoproteinemia phenotypes that are characterized by hypertriglyceridemia. <i>Human Molecular Genetics</i> , <b>2009</b> , 18, 4189-94	1.1	77
622	Left Atrial Appendage Occlusion during Cardiac Surgery to Prevent Stroke. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 2081-2091	18	77
621	Antithrombotic therapy with fondaparinux in relation to interventional management strategy in patients with ST- and non-ST-segment elevation acute coronary syndromes: an individual patient-level combined analysis of the Fifth and Sixth Organization to Assess Strategies in Ischemic Syndromes (OASIS 5 and 6) randomized trials. <i>Circulation</i> , <b>2008</b> , 118, 2038-46	4.8	76
620	Impact of resting heart rate on mortality, disability and cognitive decline in patients after ischaemic stroke. <i>European Heart Journal</i> , <b>2012</b> , 33, 2804-12	3.5	75
619	Carbohydrate intake and HDL in a multiethnic population. <i>American Journal of Clinical Nutrition</i> , <b>2007</b> , 85, 225-30	1.8	75
618	Relationship of glucose and insulin levels to the risk of myocardial infarction: a case-control study. <i>Journal of the American College of Cardiology</i> , <b>1999</b> , 33, 612-9	3.8	75
617	Stroke in the TOTAL trial: a randomized trial of routine thrombectomy vs. percutaneous coronary intervention alone in ST elevation myocardial infarction. <i>European Heart Journal</i> , <b>2015</b> , 36, 2364-72	3.5	74
616	Challenges of establishing new antithrombotic therapies in atrial fibrillation. <i>Circulation</i> , <b>2007</b> , 116, 449-58	4.8	74
615	Left Atrial Appendage Occlusion Study II (LAAOS II). <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, 1443-7	1.3	73
614	Penetrance of Polygenic Obesity Susceptibility Loci across the Body Mass Index Distribution. <i>American Journal of Human Genetics</i> , <b>2017</b> , 101, 925-938	2.5	73
613	An increased burden of common and rare lipid-associated risk alleles contributes to the phenotypic spectrum of hypertriglyceridemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , <b>2011</b> , 31, 1916-26	2.7	73

612	Dual-chamber versus ventricular pacing. Critical appraisal of current data. <i>Circulation</i> , <b>1996</b> , 94, 578-83	4.8	73
611	Stroke Outcomes in the COMPASS Trial. <i>Circulation</i> , <b>2019</b> , 139, 1134-1145	4.8	72
610	Heart Failure in Africa, Asia, the Middle East and South America: The INTER-CHF study. <i>International Journal of Cardiology</i> , <b>2016</b> , 204, 133-41	0.8	72
609	Community health worker-based intervention for adherence to drugs and lifestyle change after acute coronary syndrome: a multicentre, open, randomised controlled trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2016</b> , 4, 244-253	4.9	72
608	Efficacy and safety of apixaban compared with aspirin in the elderly: a subgroup analysis from the AVERROES trial. <i>Age and Ageing</i> , <b>2016</b> , 45, 77-83	1	72
607	Discordance analysis of apolipoprotein B and non-high density lipoprotein cholesterol as markers of cardiovascular risk in the INTERHEART study. <i>Atherosclerosis</i> , <b>2012</b> , 225, 444-9	0.8	72
606	Elevated lipoprotein(a) levels in South Asians in North America. <i>Metabolism: Clinical and Experimental</i> , <b>1998</b> , 47, 182-4	2.7	71
605	Bleeding during treatment with aspirin versus apixaban in patients with atrial fibrillation unsuitable for warfarin: the apixaban versus acetylsalicylic acid to prevent stroke in atrial fibrillation patients who have failed or are unsuitable for vitamin K antagonist treatment (AVERROES) trial. <i>Stroke</i> , <b>2012</b> , 43, 3291-7	1.8	70
604	Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non ST-segment elevation acute coronary syndromes. <i>Annals of Internal Medicine</i> , <b>2007</b> , 147, 304-10	2.5	70
603	Perioperative covert stroke in patients undergoing non-cardiac surgery (NeuroVISION): a prospective cohort study. <i>Lancet, The</i> , <b>2019</b> , 394, 1022-1029	11.5	69
602	High-sensitivity cardiac troponin I measurement for risk stratification in a stable high-risk population. <i>Clinical Chemistry</i> , <b>2011</b> , 57, 1146-53	1.4	68
601	The association of basal insulin glargine and/or n-3 fatty acids with incident cancers in patients with dysglycemia. <i>Diabetes Care</i> , <b>2014</b> , 37, 1360-6	3.9	67
600	The effect of chromosome 9p21 variants on cardiovascular disease may be modified by dietary intake: evidence from a case/control and a prospective study. <i>PLoS Medicine</i> , <b>2011</b> , 8, e1001106	3.6	67
599	Toward Fairness in Data Sharing. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 405-7	18	67
598	Availability and affordability of essential medicines for diabetes across high-income, middle-income, and low-income countries: a prospective epidemiological study. <i>Lancet Diabetes and Endocrinology</i> , <b>2018</b> , 6, 798-808	4.9	66
597	Excess of rare variants in non-genome-wide association study candidate genes in patients with hypertriglyceridemia. <i>Circulation: Cardiovascular Genetics</i> , <b>2012</b> , 5, 66-72		65
596	Dabigatran compared with warfarin in patients with atrial fibrillation and symptomatic heart failure: a subgroup analysis of the RE-LY trial. <i>European Journal of Heart Failure</i> , <b>2013</b> , 15, 1053-61	3.1	65
595	Calcium antagonists in coronary artery disease and hypertension. Time for reevaluation?. <i>Circulation</i> , <b>1995</b> , 92, 1079-82	4.8	65

594	Association of handgrip strength to cardiovascular mortality in pre-diabetic and diabetic patients: a subanalysis of the ORIGIN trial. <i>International Journal of Cardiology</i> , <b>2014</b> , 174, 458-61	0.8	64
593	Relationship between baseline haemoglobin and major bleeding complications in acute coronary syndromes. <i>European Heart Journal</i> , <b>2010</b> , 31, 50-8	3.5	64
592	Plasma renin activity predicts cardiovascular mortality in the Heart Outcomes Prevention Evaluation (HOPE) study. <i>European Heart Journal</i> , <b>2011</b> , 32, 2135-42	3.5	64
591	Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial (ONTARGET). <i>Circulation</i> , <b>2012</b> , 126, 934-41	4.8	64
590	Infarct size, ejection fraction, and mortality in diabetic patients with acute myocardial infarction treated with thrombolytic therapy. <i>American Heart Journal</i> , <b>2007</b> , 154, 743-50	1.3	64
589	Evaluation of the implantable cardioverter defibrillator in survivors of cardiac arrest: the need for randomized trials. <i>American Journal of Cardiology</i> , <b>1992</b> , 69, 959-62	0.7	64
588	A biomarker-based risk score to predict death in patients with atrial fibrillation: the ABC (age, biomarkers, clinical history) death risk score. <i>European Heart Journal</i> , <b>2018</b> , 39, 477-485	3.5	63
587	Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study. <i>Nephrology Dialysis Transplantation</i> , <b>2008</b> , 23, 645-53	1.2	63
586	Diagnostic strategies to detect glucose intolerance in a multiethnic population. <i>Diabetes Care</i> , <b>2003</b> , 26, 290-6	3.9	63
585	Relationship of anti-60 kDa heat shock protein and anti-cholesterol antibodies to cardiovascular events. <i>Circulation</i> , <b>2002</b> , 106, 2775-80	4.8	63
584	Extracranial Systemic Embolic Events in Patients With Nonvalvular Atrial Fibrillation: Incidence, Risk Factors, and Outcomes. <i>Circulation</i> , <b>2015</b> , 132, 796-803	4.8	62
583	Clinical characteristics and outcomes of young and very young adults with heart failure: The CHARM programme (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity). <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 1845-54	3.8	62
582	Association of risk factors with acute myocardial infarction in Middle Eastern countries: the INTERHEART Middle East study. <i>European Journal of Preventive Cardiology</i> , <b>2014</b> , 21, 400-10	1.2	62
581	A family-based intervention to promote healthy lifestyles in an aboriginal community in Canada. <i>Canadian Journal of Public Health</i> , <b>2007</b> , 98, 447-52	0.9	62
580	Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study. <i>American Journal of Kidney Diseases</i> , <b>2003</b> , 42, 936-42	2.2	62
579	Primary Prevention With Statin Therapy in the Elderly: New Meta-Analyses From the Contemporary JUPITER and HOPE-3 Randomized Trials. <i>Circulation</i> , <b>2017</b> , 135, 1979-1981	4.8	61
578	Effect of telmisartan on functional outcome, recurrence, and blood pressure in patients with acute mild ischemic stroke: a PROfESS subgroup analysis. <i>Stroke</i> , <b>2009</b> , 40, 3541-6	1.8	61
577	Benefit of clopidogrel according to timing of percutaneous coronary intervention in patients with acute coronary syndromes: further results from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study. <i>American Heart Journal</i> , <b>2005</b> , 150, 1177-84	1.3	61

576	Long-term cost-effectiveness of early and sustained clopidogrel therapy for up to 1 year in patients undergoing percutaneous coronary intervention after presenting with acute coronary syndromes without ST-segment elevation. <i>American Heart Journal</i> , <b>2006</b> , 151, 219-27	1.3	61
575	Health Effects of Household Solid Fuel Use: Findings from 11 Countries within the Prospective Urban and Rural Epidemiology Study. <i>Environmental Health Perspectives</i> , <b>2019</b> , 127, 57003	2.7	60
574	Procedural volume and outcomes with radial or femoral access for coronary angiography and intervention. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 954-63	3.8	60
573	Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk. <i>Hypertension</i> , <b>2015</b> , 65, 651-61	2.4	60
572	Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 854-5	3.8	60
571	Estimated glomerular filtration rate and albuminuria as predictors of outcomes in patients with high cardiovascular risk: a cohort study. <i>Annals of Internal Medicine</i> , <b>2011</b> , 154, 310-8	2.5	60
570	Environmental Profile of a Community's Health (EPOCH): an instrument to measure environmental determinants of cardiovascular health in five countries. <i>PLoS ONE</i> , <b>2010</b> , 5, e14294	1.2	60
569	Risk of intracranial haemorrhage with bolus versus infusion thrombolytic therapy: a meta-analysis. <i>Lancet, The</i> , <b>2000</b> , 356, 449-54	11.5	60
568	Variations between women and men in risk factors, treatments, cardiovascular disease incidence, and death in 27 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. <i>Lancet, The</i> , <b>2020</b> , 396, 97-109	11.5	59
567	Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis. <i>Lancet, The</i> , <b>2020</b> , 396, 968-976	11.5	59
566	Effects of dabigatran according to age in atrial fibrillation. <i>Heart</i> , <b>2017</b> , 103, 1015-1023	1.3	58
565	Comparison of dabigatran versus warfarin in diabetic patients with atrial fibrillation: Results from the RE-LY trial. <i>International Journal of Cardiology</i> , <b>2015</b> , 196, 127-31	0.8	58
564	International geographic variation in event rates in trials of heart failure with preserved and reduced ejection fraction. <i>Circulation</i> , <b>2015</b> , 131, 43-53	4.8	58
563	Performance and Validation of a Novel Biomarker-Based Stroke Risk Score for Atrial Fibrillation. <i>Circulation</i> , <b>2016</b> , 134, 1697-1707	4.8	58
562	Design and rationale of the TOTAL trial: a randomized trial of routine aspiration Thrombectomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCI. <i>American Heart Journal</i> , <b>2014</b> , 167, 315-321.e1	1.3	58
561	Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2012</b> , 5, 463-71	1.3	58
560	Usefulness of temporal changes in neurohormones as markers of ventricular remodeling and prognosis in patients with left ventricular systolic dysfunction and heart failure receiving either candesartan or enalapril or both. <i>American Journal of Cardiology</i> , <b>2005</b> , 96, 698-704	0.7	58
559	Polypill with or without Aspirin in Persons without Cardiovascular Disease. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 216-228	18	58

558	Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. <i>European Heart Journal</i> , <b>2014</b> , 35, 353-64	3.5	57
557	External applicability of the COMPASS trial: an analysis of the reduction of atherothrombosis for continued health (REACH) registry. <i>European Heart Journal</i> , <b>2018</b> , 39, 750-757a	3.5	56
556	Rivaroxaban Plus Aspirin Versus Aspirin in Relation to Vascular Risk in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 3271-3280	3.8	56
555	Ischemic pain relief in patients with acute myocardial infarction by intravenous atenolol. <i>American Heart Journal</i> , <b>1982</b> , 103, 459-67	1.3	56
554	Practice patterns and outcomes after stroke across countries at different economic levels (INTERSTROKE): an international observational study. <i>Lancet, The</i> , <b>2018</b> , 391, 2019-2027	11.5	55
553	Genetic variants associated with myocardial infarction risk factors in over 8000 individuals from five ethnic groups: The INTERHEART Genetics Study. <i>Circulation: Cardiovascular Genetics</i> , <b>2009</b> , 2, 16-25		54
552	Meta-analysis of the INSIG2 association with obesity including 74,345 individuals: does heterogeneity of estimates relate to study design?. <i>PLoS Genetics</i> , <b>2009</b> , 5, e1000694	1.4	54
551	Social disadvantage and cardiovascular disease: development of an index and analysis of age, sex, and ethnicity effects. <i>International Journal of Epidemiology</i> , <b>2006</b> , 35, 1239-45	1.9	54
550	Impact of candesartan on nonfatal myocardial infarction and cardiovascular death in patients with heart failure. <i>JAMA - Journal of the American Medical Association</i> , <b>2005</b> , 294, 1794-8	7.4	54
549	Role of Combination Antiplatelet and Anticoagulation Therapy in Diabetes Mellitus and Cardiovascular Disease: Insights From the COMPASS Trial. <i>Circulation</i> , <b>2020</b> , 141, 1841-1854	4.8	53
548	Correction of population stratification in large multi-ethnic association studies. <i>PLoS ONE</i> , <b>2008</b> , 3, e1382.2		53
547	Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease. <i>Hypertension</i> , <b>2015</b> , 65, 108-14	2.4	52
546	Angiotensin-converting enzyme 2 (ACE2) levels in relation to risk factors for COVID-19 in two large cohorts of patients with atrial fibrillation. <i>European Heart Journal</i> , <b>2020</b> , 41, 4037-4046	3.5	52
545	Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 557-65	3.1	51
544	Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study. <i>Circulation</i> , <b>2003</b> , 107, 960-5	4.8	51
543	Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. <i>American Heart Journal</i> , <b>2006</b> , 152, 86-92	1.3	51
542	Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease. <i>Circulation</i> , <b>2019</b> , 140, 529-537	4.8	50
541	Joint association of urinary sodium and potassium excretion with cardiovascular events and mortality: prospective cohort study. <i>BMJ, The</i> , <b>2019</b> , 364, l772	2.2	50



540	Alteplase for acute ischemic stroke: outcomes by clinically important subgroups in the Third International Stroke Trial. <i>Stroke</i> , <b>2015</b> , 46, 746-56	1.8	50
539	Modifiable lifestyle and social factors affect chronic kidney disease in high-risk individuals with type 2 diabetes mellitus. <i>Kidney International</i> , <b>2015</b> , 87, 784-91	2.7	50
538	Physical activity and genetic predisposition to obesity in a multiethnic longitudinal study. <i>Scientific Reports</i> , <b>2016</b> , 6, 18672	1.5	50
537	Replication of genetic associations with plasma lipoprotein traits in a multiethnic sample. <i>Journal of Lipid Research</i> , <b>2009</b> , 50, 1487-96	1.8	50
536	Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone). <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 53, 2028-35	3.8	50
535	Stroke in relation to cardiac procedures in patients with non-ST-elevation acute coronary syndrome: a study involving >18 000 patients. <i>Circulation</i> , <b>2001</b> , 104, 269-74	4.8	50
534	Interpreting Geographic Variations in Results of Randomized, Controlled Trials. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 2263-2271	18	50
533	Identifying Novel Biomarkers for Cardiovascular Events or Death in People With Dysglycemia. <i>Circulation</i> , <b>2015</b> , 132, 2297-304	4.8	49
532	Diet and Major Renal Outcomes: A Prospective Cohort Study. The NIH-AARP Diet and Health Study. <i>Journal of Renal Nutrition</i> , <b>2016</b> , 26, 288-98	0.8	49
531	Predictors of development of diabetes in patients with chronic heart failure in the Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity (CHARM) program. <i>Diabetes Care</i> , <b>2009</b> , 32, 915-20	3.9	49
530	Early invasive compared with a selective invasive strategy in women with non-ST-elevation acute coronary syndromes: a substudy of the OASIS 5 trial and a meta-analysis of previous randomized trials. <i>European Heart Journal</i> , <b>2012</b> , 33, 51-60	3.5	49
529	Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONGOING Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Inhibitor-Tolerant Subjects with Cardiovascular Disease (ONTARGET/ASCEND) trial	1.3	49
528	Associations of plasma homocysteine and the methylenetetrahydrofolate reductase C677T polymorphism with carotid intima media thickness among South Asian, Chinese and European Canadians. <i>Atherosclerosis</i> , <b>2004</b> , 176, 361-70	0.8	49
527	Patients' knowledge, attitudes, behaviour and health care experiences on the prevention, detection, management and control of hypertension in Colombia: a qualitative study. <i>PLoS ONE</i> , <b>2015</b> , 10, e0122112	1.2	48
526	Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 900-8	3.8	48
525	APOA5 genetic variants are markers for classic hyperlipoproteinemia phenotypes and hypertriglyceridemia. <i>Nature Clinical Practice Cardiovascular Medicine</i> , <b>2008</b> , 5, 730-7		48
524	Mortality and cardiovascular and respiratory morbidity in individuals with impaired FEV (PURE): an international, community-based cohort study. <i>The Lancet Global Health</i> , <b>2019</b> , 7, e613-e623	4	47
523	Prognostic importance of temporal changes in resting heart rate in heart failure patients: an analysis of the CHARM program. <i>European Heart Journal</i> , <b>2015</b> , 36, 669-75	3.5	47

522	Resource Effective Strategies to Prevent and Treat Cardiovascular Disease. <i>Circulation</i> , <b>2016</b> , 133, 742-54.8	4.8	47
521	Efficacy and safety of fondaparinux versus enoxaparin in patients with acute coronary syndromes treated with glycoprotein IIb/IIIa inhibitors or thienopyridines: results from the OASIS 5 (Fifth Organization to Assess Strategies in Ischemic Syndromes) trial. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 54, 468-76	3.8	47
520	The role of fondaparinux as an adjunct to thrombolytic therapy in acute myocardial infarction: a subgroup analysis of the OASIS-6 trial. <i>European Heart Journal</i> , <b>2008</b> , 29, 324-31	3.5	47
519	Interrelation of saturated fat, trans fat, alcohol intake, and subclinical atherosclerosis. <i>American Journal of Clinical Nutrition</i> , <b>2008</b> , 87, 168-74	1.8	47
518	The relationship between dysglycemia and atherosclerosis in South Asian, Chinese, and European individuals in Canada: a randomly sampled cross-sectional study. <i>Diabetes Care</i> , <b>2003</b> , 26, 144-9	3.9	47
517	Sodium intake and renal outcomes: a systematic review. <i>American Journal of Hypertension</i> , <b>2014</b> , 27, 1277-84	3.4	46
516	Global differences in lung function by region (PURE): an international, community-based prospective study. <i>Lancet Respiratory Medicine</i> , <b>2013</b> , 1, 599-609	8.2	46
515	Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction. <i>Circulation</i> , <b>2004</b> , 110, 1413-7	4.8	46
514	Effect of long-term therapy with ramipril in high-risk women. <i>Journal of the American College of Cardiology</i> , <b>2002</b> , 40, 693-702	3.8	46
513	The Organization to Assess Strategies for Ischemic Syndromes (OASIS) registry in patients with unstable angina. <i>American Journal of Cardiology</i> , <b>1999</b> , 84, 7M-12M	0.7	46
512	Significance of elevated MB isoenzyme with normal creatine kinase in acute myocardial infarction. <i>American Journal of Cardiology</i> , <b>1987</b> , 59, 245-50	0.7	46
511	Rivaroxaban, Aspirin, or Both to Prevent Early Coronary Bypass Graft Occlusion: The COMPASS-CABG Study. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 121-130	3.8	46
510	C-reactive protein is a bystander of cardiovascular disease. <i>European Heart Journal</i> , <b>2010</b> , 31, 2092-6	3.5	45
509	Development of food frequency questionnaires and a nutrient database for the Prospective Urban and Rural Epidemiological (PURE) pilot study in South India: methodological issues. <i>Asia Pacific Journal of Clinical Nutrition</i> , <b>2008</b> , 17, 178-85	0.3	45
508	Healthy eating and reduced risk of cognitive decline: A cohort from 40 countries. <i>Neurology</i> , <b>2015</b> , 84, 2258-65	1.7	44
507	Inequalities in the use of secondary prevention of cardiovascular disease by socioeconomic status: evidence from the PURE observational study. <i>The Lancet Global Health</i> , <b>2018</b> , 6, e292-e301	4	44
506	Aspirin in Patients With Previous Percutaneous Coronary Intervention Undergoing Noncardiac Surgery. <i>Annals of Internal Medicine</i> , <b>2018</b> , 168, 237-244	2.5	44
505	Blood pressure-lowering treatment strategies based on cardiovascular risk versus blood pressure: A meta-analysis of individual participant data. <i>PLoS Medicine</i> , <b>2018</b> , 15, e1002538	3.6	44

504	Measures of cardiovascular risk and subclinical atherosclerosis in a cohort of women with a remote history of preeclampsia. <i>Atherosclerosis</i> , <b>2013</b> , 229, 234-9	0.8	44
503	Rationale and design of the coronary artery bypass grafting surgery off or on pump revascularization study: a large international randomized trial in cardiac surgery. <i>American Heart Journal</i> , <b>2012</b> , 163, 1-6	1.3	44
502	Causal relationship between adiponectin and metabolic traits: a Mendelian randomization study in a multiethnic population. <i>PLoS ONE</i> , <b>2013</b> , 8, e66808	1.2	44
501	Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PROFESS subgroup analysis. <i>Stroke</i> , <b>2010</b> , 41, 732-8	1.8	44
500	Role of magnesium in reducing mortality in acute myocardial infarction. A review of the evidence. <i>Drugs</i> , <b>1993</b> , 46, 347-359	3.3	44
499	Studies of Left Ventricular Dysfunction (SOLVD) Registry: rationale, design, methods and description of baseline characteristics. <i>American Journal of Cardiology</i> , <b>1992</b> , 70, 347-53	0.7	44
498	Evaluating effects of treatment in subgroups of patients within a clinical trial: the case of non-Q-wave myocardial infarction and beta blockers. <i>American Journal of Cardiology</i> , <b>1990</b> , 66, 220-2	0.7	44
497	Obtaining medically meaningful answers from an overview of randomized clinical trials. <i>Statistics in Medicine</i> , <b>1987</b> , 6, 281-94	0.5	44
496	Effect of drug therapy on survival in chronic congestive heart failure. <i>American Journal of Cardiology</i> , <b>1988</b> , 62, 41A-45A	0.7	44
495	Additional events in the RE-LY trial. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 1464-5	18	43
494	Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial. <i>Diabetes Care</i> , <b>2010</b> , 33, 608-13	3.9	43
493	Sensible guidelines for the conduct of large randomized trials. <i>Clinical Trials</i> , <b>2008</b> , 5, 38-9	0.6	43
492	Preoperative N-Terminal Pro-B-Type Natriuretic Peptide and Cardiovascular Events After Noncardiac Surgery: A Cohort Study. <i>Annals of Internal Medicine</i> , <b>2020</b> , 172, 96-104	2.5	43
491	Comparison of Characteristics and Outcomes of Dabigatran Versus Warfarin in Hypertensive Patients With Atrial Fibrillation (from the RE-LY Trial). <i>American Journal of Cardiology</i> , <b>2015</b> , 116, 1204-9 <sup>0.7</sup>	0.7	42
490	Comparative impact of enalapril, candesartan or metoprolol alone or in combination on ventricular remodelling in patients with congestive heart failure. <i>European Heart Journal</i> , <b>2003</b> , 24, 1727-34	3.5	42
489	Beta-carotene, vitamin C, and vitamin E and cardiovascular diseases. <i>Current Cardiology Reports</i> , <b>2000</b> , 2, 293-9	1.1	42
488	The 24-hour heart rate behavior in long-term survivors of cardiac transplantation. <i>American Journal of Cardiology</i> , <b>1988</b> , 61, 880-4	0.7	42
487	Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes. <i>Kidney International</i> , <b>2017</b> , 91, 683-690	2.7	41

486	Prevalence and prognostic importance of precipitating factors leading to heart failure hospitalization: recurrent hospitalizations and mortality. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 295-303	3.1	41
485	Worsening renal function and outcome in heart failure patients with reduced and preserved ejection fraction and the impact of angiotensin receptor blocker treatment: data from the CHARM-study programme. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1508-1517	3.1	41
484	Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET). <i>Hypertension</i> , <b>2012</b> , 60, 1400-6	2.4	41
483	Characterizing exposure to household air pollution within the Prospective Urban Rural Epidemiology (PURE) study. <i>Environment International</i> , <b>2018</b> , 114, 307-317	4.7	40
482	Influenza vaccination and major adverse vascular events in high-risk patients. <i>Circulation</i> , <b>2012</b> , 126, 278-88	3.8	40
481	Prognostic significance of thrombocytopenia during hirudin and heparin therapy in acute coronary syndrome without ST elevation: Organization to Assess Strategies for Ischemic Syndromes (OASIS-2) study. <i>Circulation</i> , <b>2001</b> , 103, 643-50	4.8	40
480	Lack of long-term ventricular arrhythmia reduction by enalapril in heart failure. SOLVD Investigators. <i>American Journal of Cardiology</i> , <b>1995</b> , 75, 1244-9	0.7	40
479	Associations of outdoor fine particulate air pollution and cardiovascular disease in 157 436 individuals from 21 high-income, middle-income, and low-income countries (PURE): a prospective cohort study. <i>Lancet Planetary Health</i> , <b>2020</b> , 4, e235-e245	3.9	40
478	Blood CSF1 and CXCL12 as Causal Mediators of Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 300-310	3.8	39
477	Basal insulin glargine and microvascular outcomes in dysglycaemic individuals: results of the Outcome Reduction with an Initial Glargine Intervention (ORIGIN) trial. <i>Diabetologia</i> , <b>2014</b> , 57, 1325-31	2.4	39
476	Predicting myocardial infarction and other serious cardiac outcomes using high-sensitivity cardiac troponin T in a high-risk stable population. <i>Clinical Biochemistry</i> , <b>2013</b> , 46, 5-9	0.8	39
475	Lipid lowering for primary prevention. <i>Lancet</i> , <b>2009</b> , 373, 1152-5	11.5	39
474	Clinical outcomes according to baseline blood pressure in patients with a low ejection fraction in the CHARM (Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity) Program. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 2000-7	3.8	39
473	Tolerability of enalapril initiation by patients with left ventricular dysfunction: results of the medication challenge phase of the Studies of Left Ventricular Dysfunction. <i>American Heart Journal</i> , <b>1994</b> , 128, 358-64	1.3	39
472	Glycemic Index, Glycemic Load, and Cardiovascular Disease and Mortality. <i>New England Journal of Medicine</i> , <b>2021</b> , 384, 1312-1322	18	39
471	Effect of apixaban on brain infarction and microbleeds: AVERROES-MRI assessment study. <i>American Heart Journal</i> , <b>2016</b> , 178, 145-50	1.3	39
470	Major Gastrointestinal Bleeding Often Is Caused by Occult Malignancy in Patients Receiving Warfarin or Dabigatran to Prevent Stroke and Systemic Embolism From Atrial Fibrillation. <i>Clinical Gastroenterology and Hepatology</i> , <b>2017</b> , 15, 682-690	1.5	38
469	Predictors of early and late stroke following cardiac surgery. <i>Cmaj</i> , <b>2014</b> , 186, 905-11	1.3	38

468	Prevalence and prognostic impact of bundle branch block in patients with heart failure: evidence from the CHARM programme. <i>European Journal of Heart Failure</i> , <b>2007</b> , 9, 510-7	3.1	38
467	Two-year outcomes in patients admitted with non-ST elevation acute coronary syndrome: results of the OASIS registry 1 and 2. <i>Indian Heart Journal</i> , <b>2005</b> , 57, 217-25	0.4	38
466	Effects of basal insulin glargine and omega-3 fatty acid on cognitive decline and probable cognitive impairment in people with dysglycaemia: a substudy of the ORIGIN trial. <i>Lancet Diabetes and Endocrinology</i> , <b>2014</b> , 2, 562-72	4.9	37
465	Effect of candesartan on New York Heart Association functional class. Results of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , <b>2004</b> , 25, 1920-6	3.5	37
464	Gene-centric meta-analysis of lipid traits in African, East Asian and Hispanic populations. <i>PLoS ONE</i> , <b>2012</b> , 7, e50198	1.2	37
463	Household and personal air pollution exposure measurements from 120 communities in eight countries: results from the PURE-AIR study. <i>Lancet Planetary Health</i> , <b>2020</b> , 4, e451-e462	3.9	37
462	Contribution of cardiac and extra-cardiac disease burden to risk of cardiovascular outcomes varies by ejection fraction in heart failure. <i>European Journal of Heart Failure</i> , <b>2018</b> , 20, 504-510	3.1	37
461	Socioeconomic factors and use of secondary preventive therapies for cardiovascular diseases in South Asia: The PURE study. <i>European Journal of Preventive Cardiology</i> , <b>2015</b> , 22, 1261-71	1.2	36
460	Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure. <i>Stroke</i> , <b>2015</b> , 46, 667-72	1.8	36
459	Concomitant Oral Anticoagulant and Nonsteroidal Anti-Inflammatory Drug Therapy in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , <b>2018</b> , 72, 255-267	3.8	36
458	Oxygen therapy in acute coronary syndrome: are the benefits worth the risk?. <i>European Heart Journal</i> , <b>2013</b> , 34, 1630-5	3.5	36
457	Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]). <i>American Journal of Cardiology</i> , <b>2009</b> , 103, 1171-8	0.7	36
456	The Family Atherosclerosis Monitoring In earLY life (FAMILY) study: rationale, design, and baseline data of a study examining the early determinants of atherosclerosis. <i>American Heart Journal</i> , <b>2009</b> , 158, 533-9	1.3	36
455	Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board. <i>Clinical Trials</i> , <b>2007</b> , 4, 218-34	0.6	36
454	Protein intake is inversely associated with abdominal obesity in a multi-ethnic population. <i>Journal of Nutrition</i> , <b>2005</b> , 135, 1196-201	1.1	36
453	Patterns of medication use in patients with heart failure: a report from the Registry of Studies of Left Ventricular Dysfunction (SOLVD). <i>Southern Medical Journal</i> , <b>1995</b> , 88, 514-23	0.3	36
452	Are we biased in our approach to treating elderly patients with heart disease?. <i>American Journal of Cardiology</i> , <b>1991</b> , 68, 954-6	0.7	36
451	Prevalence of Prediabetes and Undiagnosed Diabetes in Patients with HFpEF and HFrEF and Associated Clinical Outcomes. <i>Cardiovascular Drugs and Therapy</i> , <b>2017</b> , 31, 545-549	1.1	35

450	Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries. <i>American Journal of Clinical Nutrition</i> , <b>2020</b> , 111, 795-803	1.8	35
449	Effect of insulin glargine and n-3FA on carotid intima-media thickness in people with dysglycemia at high risk for cardiovascular events: the glucose reduction and atherosclerosis continuing evaluation study (ORIGIN-GRACE). <i>Diabetes Care</i> , <b>2013</b> , 36, 2466-74	3.9	35
448	Association of Household Wealth Index, Educational Status, and Social Capital with Hypertension Awareness, Treatment, and Control in South Asia. <i>American Journal of Hypertension</i> , <b>2017</b> , 30, 373-381	0.7	34
447	Growth-differentiation factor 15 and risk of major bleeding in atrial fibrillation: Insights from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial. <i>American Heart Journal</i> , <b>2017</b> , 190, 94-103	1.3	34
446	Contribution of common non-synonymous variants in PCSK1 to body mass index variation and risk of obesity: a systematic review and meta-analysis with evidence from up to 331 175 individuals. <i>Human Molecular Genetics</i> , <b>2015</b> , 24, 3582-94	1.1	34
445	Association of cyclooxygenase-2 genetic variant with cardiovascular disease. <i>European Heart Journal</i> , <b>2014</b> , 35, 2242-8a	3.5	34
444	Mortality and morbidity in relation to changes in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET and TRANSCEND studies. <i>Diabetologia</i> , <b>2014</b> , 57, 2019-29	2.4	34
443	Cost of prevention. The case of lipid lowering. <i>Circulation</i> , <b>1996</b> , 93, 1774-6	4.8	34
442	Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study. <i>Neurology</i> , <b>2019</b> , 92, e1435-e1446	1.7	34
441	The household economic burden of non-communicable diseases in 18 countries. <i>BMJ Global Health</i> , <b>2020</b> , 5, e002040	2.1	33
440	Challenges in the conduct of large simple trials of important generic questions in resource-poor settings: the CREATE and ECLA trial program evaluating GIK (glucose, insulin and potassium) and low-molecular-weight heparin in acute myocardial infarction. <i>American Heart Journal</i> , <b>2004</b> , 148, 1068-78	1.3	33
439	Designing and analyzing clinical trials with composite outcomes: consideration of possible treatment differences between the individual outcomes. <i>PLoS ONE</i> , <b>2012</b> , 7, e34785	1.2	33
438	Maternal and pregnancy related predictors of cardiometabolic traits in newborns. <i>PLoS ONE</i> , <b>2013</b> , 8, e55815	1.2	33
437	Salt and cardiovascular disease: insufficient evidence to recommend low sodium intake. <i>European Heart Journal</i> , <b>2020</b> , 41, 3363-3373	3.5	33
436	Prevalence of mitral valve prolapse in ethnic groups. <i>Canadian Journal of Cardiology</i> , <b>2004</b> , 20, 511-5	1.3	33
435	Quality of individual INR control and the risk of stroke and bleeding events in atrial fibrillation patients: a nested case control analysis of the ACTIVE W study. <i>Thrombosis Research</i> , <b>2012</b> , 129, 715-9	1.7	32
434	Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REDuction Assessment with ramipril and rosiglitazone Medication (DREAM) study. <i>Diabetes Care</i> , <b>2010</b> , 33, 2250-3	3.9	32
433	Tobacco control environment: cross-sectional survey of policy implementation, social unacceptability, knowledge of tobacco health harms and relationship to quit ratio in 17 low-income, middle-income and high-income countries. <i>BMJ Open</i> , <b>2017</b> , 7, e013817	0.9	31

432	Prognostic validation of a non-laboratory and a laboratory based cardiovascular disease risk score in multiple regions of the world. <i>Heart</i> , <b>2018</b> , 104, 581-587	1.3	31
431	Relationship of the ApoE polymorphism to plasma lipid traits among South Asians, Chinese, and Europeans living in Canada. <i>Atherosclerosis</i> , <b>2009</b> , 203, 192-200	0.8	30
430	Effects of fondaparinux in patients with ST-segment elevation acute myocardial infarction not receiving reperfusion treatment. <i>European Heart Journal</i> , <b>2008</b> , 29, 315-23	3.5	30
429	Racial differences in outcome and treatment effect in congestive heart failure. <i>American Heart Journal</i> , <b>2005</b> , 150, 968-76	1.3	30
428	The COMPASS Trial: Net Clinical Benefit of Low-Dose Rivaroxaban Plus Aspirin as Compared With Aspirin in Patients With Chronic Vascular Disease. <i>Circulation</i> , <b>2020</b> , 142, 40-48	4.8	29
427	Association of Symptoms of Depression With Cardiovascular Disease and Mortality in Low-, Middle-, and High-Income Countries. <i>JAMA Psychiatry</i> , <b>2020</b> , 77, 1052-1063	4.5	29
426	Central statistical monitoring: detecting fraud in clinical trials. <i>Clinical Trials</i> , <b>2013</b> , 10, 225-35	0.6	29
425	Multi-ethnic genetic association study of carotid intima-media thickness using a targeted cardiovascular SNP microarray. <i>Stroke</i> , <b>2009</b> , 40, 3173-9	1.8	29
424	Resource utilization and costs in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Heart Journal</i> , <b>2006</b> , 27, 1447-58	3.5	29
423	Choice of clinical outcomes in randomized trials of heart failure therapies: disease-specific or overall outcomes?. <i>American Heart Journal</i> , <b>2002</b> , 143, 22-8	1.3	29
422	Diurnal variations of QT interval after cardiac transplantation. <i>American Journal of Cardiology</i> , <b>1988</b> , 61, 482-5	0.7	29
421	The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial. <i>European Journal of Preventive Cardiology</i> , <b>2014</b> , 21, 299-309	1.2	28
420	Effectiveness of preload reserve as a determinant of clinical status in patients with left ventricular systolic dysfunction. The SOLVD Investigators. <i>American Journal of Cardiology</i> , <b>1992</b> , 69, 1591-5	0.7	28
419	Classifying ethnicity utilizing the Canadian Mortality Data Base. <i>Ethnicity and Health</i> , <b>1997</b> , 2, 287-95	0.9	27
418	Effects of calcium channel blockers on survival after myocardial infarction. <i>Cardiovascular Drugs and Therapy</i> , <b>1987</b> , 1, 343-4	1.1	27
417	Bariatric Surgery and Cardiovascular Outcomes in Patients With Obesity and Cardiovascular Disease:: A Population-Based Retrospective Cohort Study. <i>Circulation</i> , <b>2021</b> , 143, 1468-1480	4.8	27
416	Age-stratified and blood-pressure-stratified effects of blood-pressure-lowering pharmacotherapy for the prevention of cardiovascular disease and death: an individual participant-level data meta-analysis. <i>Lancet, The</i> , <b>2021</b> , 398, 1053-1064	11.5	27
415	Dietary risk factors for incidence or progression of chronic kidney disease in individuals with type 2 diabetes in the European Union. <i>Nephrology Dialysis Transplantation</i> , <b>2015</b> , 30 Suppl 4, iv76-85	1.2	26

414	Mortality predictors and effects of antithrombotic therapies in atrial fibrillation: insights from ACTIVE-W. <i>European Heart Journal</i> , <b>2010</b> , 31, 2133-40	3.5	26
413	Acute and long-term effects of the angiotensin-converting enzyme inhibitor, enalapril, on adrenergic activity and sensitivity during exercise in patients with left ventricular systolic dysfunction. <i>American Heart Journal</i> , <b>1997</b> , 134, 37-43	1.3	26
412	Meta-analysis of randomized trials: looking back and looking ahead. <i>Contemporary Clinical Trials</i> , <b>1997</b> , 18, 594-601; discussion 661-6		26
411	Correlations between plasma homocysteine and folate concentrations and carotid atherosclerosis in high-risk individuals: baseline data from the Homocysteine and Atherosclerosis Reduction Trial (HART). <i>Vascular Medicine</i> , <b>2008</b> , 13, 245-53	0.7	26
410	A lifetime of prevention: the case of heart failure. <i>Circulation</i> , <b>2002</b> , 106, 2997-8	4.8	26
409	The relevance of subgroup-specific treatment effects: the Studies Of Left Ventricular Dysfunction (SOLVD) revisited. <i>American Heart Journal</i> , <b>2002</b> , 144, 941-7	1.3	26
408	Functional capacity in patients with congestive heart failure. <i>Journal of Cardiac Failure</i> , <b>2000</b> , 6, 214-9	1	26
407	Tackling NCD in LMIC: Achievements and Lessons Learned From the NHLBI-UnitedHealth Global Health Centers of Excellence Program. <i>Global Heart</i> , <b>2016</b> , 11, 5-15	1.1	26
406	Risk of stroke and other adverse outcomes in patients with perioperative atrial fibrillation 1 year after non-cardiac surgery. <i>European Heart Journal</i> , <b>2020</b> , 41, 645-651	3.5	25
405	Association of dairy consumption with metabolic syndrome, hypertension and diabetes in 147 812 individuals from 21 countries. <i>BMJ Open Diabetes Research and Care</i> , <b>2020</b> , 8,	1.5	25
404	Risk of stroke in chronic heart failure patients with preserved ejection fraction, but without atrial fibrillation: analysis of the CHARM-Preserved and I-Preserve trials. <i>European Heart Journal</i> , <b>2017</b> , 38, 742-750	3.5	25
403	Polypills: essential medicines for cardiovascular disease secondary prevention?. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 1368-70	3.8	25
402	Sodium and cardiovascular disease. <i>New England Journal of Medicine</i> , <b>2014</b> , 371, 2137-8	18	25
401	Influence of hospitalization for cardiovascular versus noncardiovascular reasons on subsequent mortality in patients with chronic heart failure across the spectrum of ejection fraction. <i>Circulation: Heart Failure</i> , <b>2014</b> , 7, 895-902	1.7	25
400	Tackling the global burden of stroke: the need for large-scale international studies. <i>Lancet Neurology</i> , <b>2009</b> , 8, 306-7	5.3	25
399	Glucose levels compared with diabetes history in the risk assessment of patients with acute myocardial infarction. <i>American Heart Journal</i> , <b>2009</b> , 157, 763-70	1.3	25
398	Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity programme. <i>European Heart Journal</i> , <b>2008</b> , 29, 3022-8	3.5	25
397	Capacity planning for cardiac catheterization: a case study. <i>Health Policy</i> , <b>2007</b> , 82, 1-11	1	25



396	Nutrition labelling, marketing techniques, nutrition claims and health claims on chip and biscuit packages from sixteen countries. <i>Public Health Nutrition</i> , <b>2016</b> , 19, 998-1007	0.8	25
395	Association Between Low-Dose Rivaroxaban With or Without Aspirin and Ischemic Stroke Subtypes: A Secondary Analysis of the COMPASS Trial. <i>JAMA Neurology</i> , <b>2020</b> , 77, 43-48	4.7	25
394	Effects of bidi smoking on all-cause mortality and cardiorespiratory outcomes in men from south Asia: an observational community-based substudy of the Prospective Urban Rural Epidemiology Study (PURE). <i>The Lancet Global Health</i> , <b>2017</b> , 5, e168-e176	4	24
393	Digoxin-mortality: randomized vs. observational comparison in the DIG trial. <i>European Heart Journal</i> , <b>2019</b> , 40, 3336-3341	3.5	24
392	Rivaroxaban Plus Aspirin in Patients With Vascular Disease and Renal Dysfunction: From the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 2243-2250	3.8	24
391	Accumulation of Deficits as a Key Risk Factor for Cardiovascular Morbidity and Mortality: A Pooled Analysis of 154000 Individuals. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e014686	1.4	24
390	Population-Attributable Fractions of Modifiable Lifestyle Factors for CKD and Mortality in Individuals With Type 2 Diabetes: A Cohort Study. <i>American Journal of Kidney Diseases</i> , <b>2016</b> , 68, 29-40	2.2	24
389	Peripheral Blood MCEMP1 Gene Expression as a Biomarker for Stroke Prognosis. <i>Stroke</i> , <b>2016</b> , 47, 652-81.8	1.8	24
388	The mini-mental state examination, clinical factors, and motor vehicle crash risk. <i>Journal of the American Geriatrics Society</i> , <b>2014</b> , 62, 1419-26	1.4	24
387	The environmental profile of a community's health: a cross-sectional study on tobacco marketing in 16 countries. <i>Bulletin of the World Health Organization</i> , <b>2015</b> , 93, 851-61G	2	24
386	Patient and System-Related Delays of Emergency Medical Services Use in Acute ST-Elevation Myocardial Infarction: Results from the Third Gulf Registry of Acute Coronary Events (Gulf RACE-3Ps). <i>PLoS ONE</i> , <b>2016</b> , 11, e0147385	1.2	24
385	Predictors, Prognosis, and Management of New Clinically Important Atrial Fibrillation After Noncardiac Surgery: A Prospective Cohort Study. <i>Anesthesia and Analgesia</i> , <b>2017</b> , 125, 162-169	1	23
384	Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk. <i>European Heart Journal</i> , <b>2019</b> , 40, 2032-2043	3.5	23
383	Randomized controlled trial of influenza vaccine in patients with heart failure to reduce adverse vascular events (IVVE): Rationale and design. <i>American Heart Journal</i> , <b>2019</b> , 212, 36-44	1.3	23
382	Urgent surgery or procedures in patients taking dabigatran or warfarin: Analysis of perioperative outcomes from the RE-LY trial. <i>Thrombosis Research</i> , <b>2016</b> , 139, 77-81	1.7	23
381	Rationale and design of the steroids in cardiac surgery trial. <i>American Heart Journal</i> , <b>2014</b> , 167, 660-5	1.3	23
380	Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme. <i>Diabetes Research and Clinical Practice</i> , <b>2009</b> , 83, 387-93	1.6	23
379	The functional variant rs1048990 in PSMA6 is associated with susceptibility to myocardial infarction in a Chinese population. <i>Atherosclerosis</i> , <b>2009</b> , 206, 199-203	0.8	23

378	Efficacy and tolerability of adding an angiotensin receptor blocker in patients with heart failure already receiving an angiotensin-converting inhibitor plus aldosterone antagonist, with or without a beta blocker. Findings from the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM)-Added trial. <i>European Journal of Heart Failure</i> , <b>2008</b> , 10, 157-63	3.1	23
377	Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients. <i>European Heart Journal</i> , <b>2007</b> , 28, 1382-8	3.5	23
376	Prevalence, awareness, treatment and control of hypertension in rural and urban communities in Latin American countries. <i>Journal of Hypertension</i> , <b>2019</b> , 37, 1813-1821	0.5	23
375	Secondary CV Prevention in South America in a Community Setting: The PURE Study. <i>Global Heart</i> , <b>2017</b> , 12, 305-313	1.1	23
374	Bleeding and New Cancer Diagnosis in Patients With Atherosclerosis. <i>Circulation</i> , <b>2019</b> , 140, 1451-1459	4.8	22
373	Gene-centric meta-analyses for central adiposity traits in up to 57 412 individuals of European descent confirm known loci and reveal several novel associations. <i>Human Molecular Genetics</i> , <b>2014</b> , 23, 2498-510	1.1	22
372	Marital status, education, and risk of acute myocardial infarction in Mainland China: the INTER-HEART study. <i>Journal of Epidemiology</i> , <b>2012</b> , 22, 123-9	0.9	22
371	Effects of telmisartan on glucose levels in people at high risk for cardiovascular disease but free from diabetes: the TRANSCEND study. <i>Diabetes Care</i> , <b>2011</b> , 34, 1902-7	3.9	22
370	Fondaparinux compared to enoxaparin in patients with acute coronary syndromes without ST-segment elevation: outcomes and treatment effect across different levels of risk. <i>American Heart Journal</i> , <b>2009</b> , 157, 502-8	1.3	22
369	Preventing vascular events due to elevated blood pressure. <i>Circulation</i> , <b>2006</b> , 113, 2166-8	4.8	22
368	Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors. <i>American Journal of Cardiovascular Drugs</i> , <b>2002</b> , 2, 157-62	0.9	22
367	Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 311-8	1.3	21
366	Elevated cholesteryl ester transfer protein (CETP) activity, a major determinant of the atherogenic dyslipidemia, and atherosclerotic cardiovascular disease in South Asians. <i>European Journal of Preventive Cardiology</i> , <b>2015</b> , 22, 468-77	1.2	21
365	Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). <i>Circulation</i> , <b>2020</b> , 141, 1141-1151	4.8	21
364	Severity of renal impairment in patients with heart failure and atrial fibrillation: implications for non-vitamin K antagonist oral anticoagulant dose adjustment. <i>European Journal of Heart Failure</i> , <b>2016</b> , 18, 1162-71	3.1	21
363	Association of Urinary Sodium Excretion With Blood Pressure and Cardiovascular Clinical Events in 17,033 Latin Americans. <i>American Journal of Hypertension</i> , <b>2016</b> , 29, 796-805	0.7	21
362	Effect of PON1 Q192R genetic polymorphism on clopidogrel efficacy and cardiovascular events in the Clopidogrel in the Unstable Angina to Prevent Recurrent Events trial and the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events. <i>Circulation: Cardiovascular Genetics</i> , <b>2012</b> , 5, 250-6		21
361	Reevaluation by high-performance liquid chromatography: clinical significance of microalbuminuria in individuals at high risk of cardiovascular disease in the Heart Outcomes Prevention Evaluation (HOPE) Study. <i>American Journal of Kidney Diseases</i> , <b>2006</b> , 48, 889-96	2.2	21

360	Effect of angiotensin-converting enzyme inhibition on functional class in patients with left ventricular systolic dysfunction--a meta-analysis. <i>European Journal of Heart Failure</i> , <b>2006</b> , 8, 90-6	3.1	21
359	Direct thrombin inhibitors in acute coronary syndromes: effect in patients undergoing early percutaneous coronary intervention. <i>European Heart Journal</i> , <b>2005</b> , 26, 2396-403	3.5	21
358	The role of serum myoglobin in the detection and measurement of myocardial infarction. <i>Clinica Chimica Acta</i> , <b>1980</b> , 106, 17-28	1.6	21
357	Social disparities explain differences in hypertension prevalence, detection and control in Colombia. <i>Journal of Hypertension</i> , <b>2016</b> , 34, 2344-2352	0.5	21
356	Coronary Artery Disease in Asian Indians: Prevalence and Risk Factors. <i>Asian American and Pacific Islander Journal of Health</i> , <b>1993</b> , 1, 163-175		21
355	Assessment of Dietary Sodium and Potassium in Canadians Using 24-Hour Urinary Collection. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 319-26	1.3	20
354	Assessing global risk factors for non-fatal injuries from road traffic accidents and falls in adults aged 35-70 years in 17 countries: a cross-sectional analysis of the Prospective Urban Rural Epidemiological (PURE) study. <i>Injury Prevention</i> , <b>2016</b> , 22, 92-8	1.2	20
353	Genetic information and the prediction of incident type 2 diabetes in a high-risk multiethnic population: the EpiDREAM genetic study. <i>Diabetes Care</i> , <b>2013</b> , 36, 2836-42	3.9	20
352	Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2013</b> , 6, 31-8	1.5	20
351	Effect of Body Mass Index on Clinical Events After Acute Coronary Syndromes. <i>American Journal of Cardiology</i> , <b>2017</b> , 120, 1453-1459	0.7	20
350	Incidental magnetic resonance diffusion-weighted imaging-positive lesions are rare in neurologically asymptomatic community-dwelling adults. <i>Stroke</i> , <b>2014</b> , 45, 2115-7	1.8	20
349	Efficacy and safety of apixaban compared with aspirin in patients who previously tried but failed treatment with vitamin K antagonists: results from the AVERROES trial. <i>European Heart Journal</i> , <b>2014</b> , 35, 1856-63	3.5	20
348	The effects of apixaban on hospitalizations in patients with different types of atrial fibrillation: insights from the AVERROES trial. <i>European Heart Journal</i> , <b>2013</b> , 34, 2752-9	3.5	20
347	Screening for dysglycemia in overweight youth presenting for weight management. <i>Diabetes Care</i> , <b>2012</b> , 35, 711-6	3.9	20
346	Dysglycemia and a history of reproductive risk factors. <i>Diabetes Care</i> , <b>2008</b> , 31, 1635-8	3.9	20
345	The inflammatory hypothesis: any progress in risk stratification and therapeutic targets?. <i>Circulation</i> , <b>2006</b> , 114, 1557-60	4.8	20
344	Patient perception of the effect of treatment with candesartan in heart failure. Results of the candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) programme. <i>European Journal of Heart Failure</i> , <b>2005</b> , 7, 650-6	3.1	20
343	Safety outcomes in meta-analyses of phase 2 vs phase 3 randomized trials: Intracranial hemorrhage in trials of bolus thrombolytic therapy. <i>JAMA - Journal of the American Medical Association</i> , <b>2001</b> , 285, 444-50	7.4	20

342	Association of ultra-processed food intake with risk of inflammatory bowel disease: prospective cohort study. <i>BMJ, The</i> , <b>2021</b> , 374, n1554	2.2	20
341	Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients. <i>Hypertension</i> , <b>2017</b> , 70, 938-948	2.4	19
340	Effect of Basal Insulin Glargine on First and Recurrent Episodes of Heart Failure Hospitalization: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention). <i>Circulation</i> , <b>2018</b> , 137, 88-90	4.8	19
339	Impact of Clopidogrel Therapy on Mortality and Cancer in Patients With Cardiovascular and Cerebrovascular Disease: A Patient-Level Meta-Analysis. <i>Circulation: Cardiovascular Interventions</i> , <b>2018</b> , 11, e005795	1.1	19
338	Incremental value of left ventricular systolic and diastolic function to determine outcome in patients with acute ST-segment elevation myocardial infarction: the echocardiographic substudy of the OASIS-6 trial. <i>Echocardiography</i> , <b>2014</b> , 31, 569-78	0.3	19
337	Impact of hospitalization for acute coronary events on subsequent mortality in patients with chronic heart failure. <i>European Heart Journal</i> , <b>2009</b> , 30, 338-45	3.5	19
336	Influence of beta blockade on exercise capacity and heart rate response after human orthotopic and heterotopic cardiac transplantation. <i>American Journal of Cardiology</i> , <b>1989</b> , 64, 636-41	0.7	19
335	White Rice Intake and Incident Diabetes: A Study of 132,373 Participants in 21 Countries. <i>Diabetes Care</i> , <b>2020</b> , 43, 2643-2650	3.9	19
334	Long-term exposure to outdoor and household air pollution and blood pressure in the Prospective Urban and Rural Epidemiological (PURE) study. <i>Environmental Pollution</i> , <b>2020</b> , 262, 114197	3.6	18
333	The cost implications of off-pump versus on-pump coronary artery bypass graft surgery at one year. <i>Annals of Thoracic Surgery</i> , <b>2014</b> , 98, 1620-5	0.5	18
332	Aliskiren alone or with other antihypertensives in the elderly with borderline and stage 1 hypertension: the APOLLO trial. <i>European Heart Journal</i> , <b>2014</b> , 35, 1743-51	3.5	18
331	The HOPE study and diabetes. <i>Lancet, The</i> , <b>2000</b> , 355, 1183-1184	11.5	18
330	Calcium antagonists in the treatment of ischemic heart disease: myocardial infarction. <i>Coronary Artery Disease</i> , <b>1994</b> , 5, 21-6	0.3	18
329	Genetic determinants of warfarin maintenance dose and time in therapeutic treatment range: a RE-LY genomics substudy. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 1425-39	0.5	18
328	Challenges in management and prevention of ischemic heart disease in low socioeconomic status people in LLMICs. <i>BMC Medicine</i> , <b>2019</b> , 17, 209	2.9	18
327	Major Bleeding in Patients With Coronary or Peripheral Artery Disease Treated With Rivaroxaban Plus Aspirin. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 1519-1528	3.8	17
326	Design of a Randomized Placebo-Controlled Trial to Assess Dabigatran and Omeprazole in Patients with Myocardial Injury after Noncardiac Surgery (MANAGE). <i>Canadian Journal of Cardiology</i> , <b>2018</b> , 34, 295-302	1.3	17
325	Effect of comorbidities on outcomes and angiotensin converting enzyme inhibitor effects in patients with predominantly left ventricular dysfunction and heart failure. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 325-33	3.1	17

324	Computationally estimated apolipoproteins B and A1 in predicting cardiovascular risk. <i>Atherosclerosis</i> , <b>2013</b> , 226, 245-51	0.8	17
323	Associations of Fish Consumption With Risk of Cardiovascular Disease and Mortality Among Individuals With or Without Vascular Disease From 58 Countries. <i>JAMA Internal Medicine</i> , <b>2021</b> , 181, 631-649	3.2	17
322	Risk factors and clinical outcomes in chronic coronary and peripheral artery disease: An analysis of the randomized, double-blind COMPASS trial. <i>European Journal of Preventive Cardiology</i> , <b>2020</b> , 27, 296-307	1.7	17
321	Household, Community, Sub-National and Country-level Predictors of Primary Cooking Fuel Switching in Nine Countries from the PURE Study. <i>Environmental Research Letters</i> , <b>2019</b> , 14,	2.3	16
320	The INVICTUS rheumatic heart disease research program: Rationale, design and baseline characteristics of a randomized trial of rivaroxaban compared to vitamin K antagonists in rheumatic valvular disease and atrial fibrillation. <i>American Heart Journal</i> , <b>2020</b> , 225, 69-77	1.3	16
319	Resource and Infrastructure-Appropriate Management of ST-Segment Elevation Myocardial Infarction in Low- and Middle-Income Countries. <i>Circulation</i> , <b>2020</b> , 141, 2004-2025	4.8	16
318	Why do people not take life-saving medications? The case of statins. <i>Lancet, The</i> , <b>2016</b> , 388, 943-5	11.5	16
317	Perioperative Aspirin for Prevention of Venous Thromboembolism: The PeriOperative ISchema Evaluation-2 Trial and a Pooled Analysis of the Randomized Trials. <i>Anesthesiology</i> , <b>2016</b> , 125, 1121-1129	1.2	16
316	Long-term evaluation of dabigatran 150 vs. 110 mg twice a day in patients with non-valvular atrial fibrillation. <i>Europace</i> , <b>2016</b> , 18, 973-8	1	16
315	The Evolution of $\beta$ Blockers in Coronary Artery Disease and Heart Failure (Part 1/5). <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 672-682	3.8	16
314	Methylprednisolone Does Not Reduce Persistent Pain after Cardiac Surgery. <i>Anesthesiology</i> , <b>2015</b> , 123, 1404-10	1.2	16
313	Physical activity levels, sport activities, and risk of acute myocardial infarction: results of the INTERHEART study in China. <i>Angiology</i> , <b>2014</b> , 65, 113-21	0.6	16
312	Rationale and design of a randomized controlled trial evaluating community health worker-based interventions for the secondary prevention of acute coronary syndromes in India (SPREAD). <i>American Heart Journal</i> , <b>2014</b> , 168, 690-7	1.3	16
311	Combination therapy to prevent cardiovascular disease: slow progress. <i>JAMA - Journal of the American Medical Association</i> , <b>2013</b> , 309, 1595-6	7.4	16
310	Polypill: the evidence and the promise. <i>Current Opinion in Lipidology</i> , <b>2009</b> , 20, 453-9	1.3	16
309	Early versus delayed enalapril in patients with left ventricular systolic dysfunction: impact on morbidity and mortality 15 years after the SOLVD trial. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 47, 1904-5	3.8	16
308	Challenges in the conduct and interpretation of phase II (pilot) randomized trials. <i>American Heart Journal</i> , <b>2000</b> , 139, S136-42	1.3	16
307	Verapamil following uncomplicated myocardial infarction: promising, but not proven. <i>American Journal of Cardiology</i> , <b>1996</b> , 77, 421-2	0.7	16

306	ACE and Type 2 Diabetes Risk: A Mendelian Randomization Study. <i>Diabetes Care</i> , <b>2020</b> , 43, 835-842	3.9	16
305	Associations of unprocessed and processed meat intake with mortality and cardiovascular disease in 21 countries [Prospective Urban Rural Epidemiology (PURE) Study]: a prospective cohort study. <i>American Journal of Clinical Nutrition</i> , <b>2021</b> , 114, 1049-1058	1.8	16
304	Resting heart rate and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk analysis from the ONTARGET/TRANSCEND trials. <i>European Heart Journal</i> , <b>2020</b> , 41, 231-238	3.5	16
303	Fixed-dose combination therapies with and without aspirin for primary prevention of cardiovascular disease: an individual participant data meta-analysis. <i>Lancet, The</i> , <b>2021</b> , 398, 1133-1146	11.5	16
302	Increased occurrence of diabetes in people with ischemic cardiovascular disease and general and abdominal obesity. <i>Canadian Journal of Cardiology</i> , <b>2003</b> , 19, 1387-91	1.3	16
301	Impact of a Genetic Risk Score on Myocardial Infarction Risk Across Different Ethnic Populations. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 1440-1446	1.3	15
300	Cardiovascular risk factor reduction by community health workers in rural India: A cluster randomized trial. <i>American Heart Journal</i> , <b>2019</b> , 216, 9-19	1.3	15
299	Apixaban-Calibrated Anti-FXa Activity in Relation to Outcome Events and Clinical Characteristics in Patients with Atrial Fibrillation: Results from the AVERROES Trial. <i>TH Open</i> , <b>2017</b> , 1, e139-e145	0.9	15
298	Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , <b>2013</b> , 8, 233-40	1.8	15
297	Iatrogenic adverse events in the coronary care unit. <i>Circulation: Cardiovascular Quality and Outcomes</i> , <b>2009</b> , 2, 437-42	1.3	15
296	Issues Regarding the Use of Heparin Following Streptokinase Therapy. <i>Journal of Thrombosis and Thrombolysis</i> , <b>1995</b> , 2, 5-10	1.2	15
295	World Heart Federation Cholesterol Roadmap. <i>Global Heart</i> , <b>2017</b> , 12, 179-197.e5	1.1	15
294	Blood HER2 and Uromodulin as Causal Mediators of CKD. <i>Journal of the American Society of Nephrology: JASN</i> , <b>2018</b> , 29, 1326-1335	3.2	14
293	Health-Related Quality of Life and Mortality in Heart Failure: The Global Congestive Heart Failure Study of 23 000 Patients From 40 Countries. <i>Circulation</i> , <b>2021</b> , 143, 2129-2142	4.8	14
292	Associations of cereal grains intake with cardiovascular disease and mortality across 21 countries in Prospective Urban and Rural Epidemiology study: prospective cohort study. <i>BMJ, The</i> , <b>2021</b> , 372, m4948 <sup>2.2</sup>	2.2	14
291	Clinical Perspective on Antihypertensive Drug Treatment in Adults With Grade 1 Hypertension and Low-to-Moderate Cardiovascular Risk: An International Expert Consultation. <i>Current Problems in Cardiology</i> , <b>2017</b> , 42, 198-225	1	13
290	Should Patients With Cardiovascular Risk Factors Receive Intensive Treatment of Hypertension to . <i>Circulation</i> , <b>2016</b> , 134, 1311-1313	4.8	13
289	Prognostic usefulness of left ventricular hypertrophy by electrocardiography in patients with atrial fibrillation (from the Randomized Evaluation of Long-Term Anticoagulant Therapy Study). <i>American Journal of Cardiology</i> , <b>2014</b> , 113, 669-75	0.7	13

288	Congestive heart failure complicating non-ST segment elevation acute coronary syndrome: incidence, predictors, and clinical outcomes. <i>Canadian Journal of Physiology and Pharmacology</i> , <b>2005</b> , 83, 98-103	0.7	13
287	A novel method to evaluate the community built environment using photographs--Environmental Profile of a Community Health (EPOCH) photo neighbourhood evaluation tool. <i>PLoS ONE</i> , <b>2014</b> , 9, e111004	1.2	13
286	Clinical characteristics and outcomes of patients with angina and heart failure in the CHARM (Candesartan in Heart Failure Assessment of Reduction in Mortality and Morbidity) Programme. <i>European Journal of Heart Failure</i> , <b>2015</b> , 17, 196-204	3.1	12
285	The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct. <i>American Heart Journal</i> , <b>2018</b> , 206, 72-79	1.3	12
284	The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study. <i>Nature Clinical Practice Cardiovascular Medicine</i> , <b>2009</b> , 6, 96-7		12
283	Effects of enalapril, candesartan or both on neurohumoral activation and LV volumes and function in patients with heart failure not treated with a beta-blocker. <i>Therapeutic Advances in Cardiovascular Disease</i> , <b>2009</b> , 3, 113-21	0.3	12
282	Piloting a novel algorithm for glucose control in the coronary care unit: the RECREATE (REsearching Coronary REDuction by Appropriately Targeting Euglycemia) trial. <i>Diabetes Care</i> , <b>2012</b> , 35, 19-24	3.9	12
281	Clinical research and trials in developing countries. <i>Statistics in Medicine</i> , <b>2002</b> , 21, 2859-67	0.5	12
280	Rivaroxaban and Aspirin in Patients With Symptomatic Lower Extremity Peripheral Artery Disease: A Subanalysis of the COMPASS Randomized Clinical Trial. <i>JAMA Cardiology</i> , <b>2021</b> , 6, 21-29	4	12
279	Effects of Trypanocidal Treatment on Echocardiographic Parameters in Chagas Cardiomyopathy and Prognostic Value of Wall Motion Score Index: A BENEFIT Trial Echocardiographic Substudy. <i>Journal of the American Society of Echocardiography</i> , <b>2019</b> , 32, 286-295.e3	1.1	12
278	Cardiac Biomarkers and Left Ventricular Hypertrophy in Relation to Outcomes in Patients With Atrial Fibrillation: Experiences From the RE-LY Trial. <i>Journal of the American Heart Association</i> , <b>2019</b> , 8, e010107	1.4	12
277	Effect of methylprednisolone on acute kidney injury in patients undergoing cardiac surgery with a cardiopulmonary bypass pump: a randomized controlled trial. <i>Cmaj</i> , <b>2019</b> , 191, E247-E256	1.3	11
276	Association of nut intake with risk factors, cardiovascular disease, and mortality in 16 countries from 5 continents: analysis from the Prospective Urban and Rural Epidemiology (PURE) study. <i>American Journal of Clinical Nutrition</i> , <b>2020</b> , 112, 208-219	1.8	11
275	Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. <i>European Heart Journal</i> , <b>2020</b> , 41, 2848-2859	3.5	11
274	From ACE Inhibitors/ARBs to ARNIs in Coronary Artery Disease and Heart Failure (Part 2/5). <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 74, 683-698	3.8	11
273	What information should a sponsor of a randomized trial receive during its conduct?. <i>Clinical Trials</i> , <b>2011</b> , 8, 716-9	0.6	11
272	Should angiotensin-converting enzyme-inhibitors be used to improve outcome in patients with coronary artery disease and 'preserved' left ventricular function?. <i>European Heart Journal</i> , <b>2006</b> , 27, 2154-7	2.5	11
271	Design, baseline characteristics, and preliminary clinical results of the Organization to Assess Strategies for Ischemic Syndromes-2 (OASIS-2) trial. <i>American Journal of Cardiology</i> , <b>1999</b> , 84, 20M-25M	0.7	11

270	The effect of treatment on survival in congestive heart failure. <i>Clinical Cardiology</i> , <b>1992</b> , 15, 323-9	0.7	11
269	The spectrum of the dyslipidemia in Colombia: The PURE study. <i>International Journal of Cardiology</i> , <b>2019</b> , 284, 111-117	0.8	11
268	Development, Testing, and Implementation of a Training Curriculum for Nonphysician Health Workers to Reduce Cardiovascular Disease. <i>Global Heart</i> , <b>2018</b> , 13, 93-100.e1	1.1	11
267	Global variations in the prevalence, treatment, and impact of atrial fibrillation in a multi-national cohort of 153 152 middle-aged individuals. <i>Cardiovascular Research</i> , <b>2021</b> , 117, 1523-1531	2.5	11
266	Long-term Effects of Statins, Blood Pressure-Lowering, and Both on Erectile Function in Persons at Intermediate Risk for Cardiovascular Disease: A Substudy of the Heart Outcomes Prevention Evaluation-3 (HOPE-3) Randomized Controlled Trial. <i>Canadian Journal of Cardiology</i> , <b>2018</b> , 34, 38-44	1.3	10
265	Knowledge, opinions and compliance related to the 100% smoke-free law in hospitality venues in Kampala, Uganda: cross-sectional results from the. <i>BMJ Open</i> , <b>2018</b> , 8, e017601	0.9	10
264	Dabigatran vs. warfarin in relation to the presence of left ventricular hypertrophy in patients with atrial fibrillation- the Randomized Evaluation of Long-term anticoagulation therapy (RE-LY) study. <i>Europace</i> , <b>2018</b> , 20, 253-262	1	10
263	Effectiveness and outcome of management strategies for dabigatran- or warfarin-related major bleeding events. <i>Thrombosis Research</i> , <b>2016</b> , 140, 81-88	1.7	10
262	Modification of outcomes with aspirin or apixaban in relation to female and male sex in patients with atrial fibrillation: a secondary analysis of the AVERROES study. <i>Stroke</i> , <b>2014</b> , 45, 2127-30	1.8	10
261	Is the superiority of apoB over non-HDL-C as a marker of cardiovascular risk in the INTERHEART study due to confounding by related variables?. <i>Journal of Clinical Lipidology</i> , <b>2013</b> , 7, 626-31	1.2	10
260	Measuring Sodium Intake in Populations: Simple Is Best?. <i>American Journal of Hypertension</i> , <b>2015</b> , 28, 1303-5	0.7	10
259	Randomized trial of fondaparinux versus heparin to prevent graft failure after coronary artery bypass grafting: the Fonda CABG study. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2011</b> , 32, 378-85	1.2	10
258	Canadian Network and Centre for Trials Internationally (CANNeCTIN): a national network for Canadian-led trials in cardiovascular diseases and diabetes mellitus. <i>Canadian Journal of Cardiology</i> , <b>2010</b> , 26, 353-8	1.3	10
257	The Indian Polycap Study (TIPS) [Authors' reply. <i>Lancet, The</i> , <b>2009</b> , 374, 782	11.5	10
256	Contrasting Associations Between Diabetes and Cardiovascular Mortality Rates in Low-, Middle-, and High-Income Countries: Cohort Study Data From 143,567 Individuals in 21 Countries in the PURE Study. <i>Diabetes Care</i> , <b>2020</b> , 43, 3094-3101	3.9	10
255	Adverse health impacts of cooking with kerosene: A multi-country analysis within the Prospective Urban and Rural Epidemiology Study. <i>Environmental Research</i> , <b>2020</b> , 188, 109851	3.1	10
254	The SPRINT and the HOPE-3 Trial in the Context of Other Blood Pressure-Lowering Trials. <i>JAMA Cardiology</i> , <b>2016</b> , 1, 857-858	4	10
253	Variations in incidence of venous thromboembolism in low-, middle-, and high-income countries. <i>Cardiovascular Research</i> , <b>2021</b> , 117, 576-584	2.5	10



252	Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. <i>Journal of the American Heart Association</i> , <b>2020</b> , 9, e018984	1.4	9
251	Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: an RE-LY AF registry analysis. <i>Europace</i> , <b>2020</b> , 22, 870-877	1	9
250	Rationale, design, and baseline participant characteristics in the MRI and cognitive substudy of the cardiovascular outcomes for people using anticoagulation strategies trial. <i>International Journal of Stroke</i> , <b>2019</b> , 14, 270-281	2	9
249	The population risks of dietary salt excess are exaggerated. <i>Canadian Journal of Cardiology</i> , <b>2014</b> , 30, 507-12	1.3	9
248	Mendelian Genes and Risk of Intracerebral Hemorrhage and Small-Vessel Ischemic Stroke in Sporadic Cases. <i>Stroke</i> , <b>2017</b> , 48, 2263-2265	1.8	9
247	Heart rate and blood pressure interactions in the development of erectile dysfunction in high-risk cardiovascular patients. <i>European Journal of Preventive Cardiology</i> , <b>2014</b> , 21, 272-80	1.2	9
246	Steroids In caRdiac Surgery (SIRS) trial: acute kidney injury substudy protocol of an international randomised controlled trial. <i>BMJ Open</i> , <b>2014</b> , 4, e004842	0.9	9
245	Body-mass index, abdominal adiposity, and cardiovascular risk. <i>Lancet, The</i> , <b>2011</b> , 378, 226-7; author reply 228	11.5	9
244	Efficacy and safety of angiotensin receptor blockade are not modified by aspirin in patients with chronic heart failure: a cohort study from the Candesartan in Heart failure--Assessment of Reduction in Mortality and morbidity (CHARM) programme. <i>European Journal of Heart Failure</i> , <b>2010</b> , 12, 738-45	3.1	9
243	Underuse of evidence-based warfarin dosing methods for atrial fibrillation patients. <i>Thrombosis Research</i> , <b>2010</b> , 125, e128-31	1.7	9
242	Efficacy and safety of fondaparinux in patients with ST-segment elevation myocardial infarction across the age spectrum. Results from the Organization for the Assessment of Strategies for Ischemic Syndromes 6 (OASIS-6) trial. <i>American Heart Journal</i> , <b>2010</b> , 160, 1049-55	1.3	9
241	The fluid study protocol: a randomized controlled study on the effects of bioimpedance analysis and vitamin D on left ventricular mass in peritoneal dialysis patients. <i>Peritoneal Dialysis International</i> , <b>2011</b> , 31, 529-36	0.9	9
240	Impact of ramipril on the circadian periodicity of acute myocardial infarction. <i>American Journal of Cardiology</i> , <b>2006</b> , 98, 758-60	0.7	9
239	Factors influencing exercise performance in patients with left ventricular dysfunction. SOLVD Investigators. Studies of Left Ventricular Dysfunction. <i>Journal of Cardiac Failure</i> , <b>1998</b> , 4, 159-67	1	9
238	Neurohumoral variability in left ventricular dysfunction. SOLVD Investigators. Studies of Left Ventricular Dysfunction. <i>American Journal of Cardiology</i> , <b>1995</b> , 75, 354-9	0.7	9
237	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 78, 14-23	3.8	9
236	Commentary: Accepting what we don't know will lead to progress. <i>International Journal of Epidemiology</i> , <b>2016</b> , 45, 260-2	1.9	8
235	Evolving evidence about diet and health. <i>Lancet Public Health, The</i> , <b>2018</b> , 3, e408-e409	6.8	8

234	Off-pump or on-pump coronary-artery bypass grafting. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 196-18		8
233	Extreme sodium reductions for the entire population: zealotry or evidence based?. <i>American Journal of Hypertension</i> , <b>2013</b> , 26, 1187-90	0.7	8
232	In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events. <i>PLoS ONE</i> , <b>2010</b> , 5, e13694	1.2	8
231	Factors of importance for QRS complex recovery after acute myocardial infarction. <i>Acta Medica Scandinavica</i> , <b>1982</b> , 211, 157-62		8
230	Coronary Artery Bypass Grafting Surgery Off- or On-pump Revascularisation Study (CORONARY): kidney substudy analytic protocol of an international randomised controlled trial. <i>BMJ Open</i> , <b>2012</b> , 2, e001080	0.9	8
229	What is the economic value of digoxin therapy in congestive heart failure patients? Results from the DIG trial. <i>Journal of Cardiac Failure</i> , <b>2006</b> , 12, 336-42	1	8
228	The role of digitalis in the treatment of heart failure. <i>Coronary Artery Disease</i> , <b>1999</b> , 10, 353-60	0.3	8
227	Effect of Colchicine vs Usual Care Alone on Intubation and 28-Day Mortality in Patients Hospitalized With COVID-19: A Randomized Clinical Trial.. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2141328	2.9	8
226	Variations in knowledge, awareness and treatment of hypertension and stroke risk by country income level. <i>Heart</i> , <b>2020</b> ,	1.3	8
225	The repeatability of self reported physical activity patterns in rural South India. <i>Asia Pacific Journal of Clinical Nutrition</i> , <b>2009</b> , 18, 71-5	0.3	8
224	The Effects of Steroids on Coagulation Dysfunction Induced by Cardiopulmonary Bypass: A Steroids in Cardiac Surgery (SIRS) Trial Substudy. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , <b>2017</b> , 29, 35-44	0.2	7
223	Five-Year Outcomes after Off-Pump or On-Pump Coronary-Artery Bypass Grafting. <i>New England Journal of Medicine</i> , <b>2017</b> , 376, 894-895	18	7
222	Variation at the DPP4 locus influences apolipoprotein B levels in South Asians and exhibits heterogeneity in Europeans related to BMI. <i>Diabetologia</i> , <b>2014</b> , 57, 738-45	2.4	7
221	Metabolic effects of telmisartan in subjects with abdominal obesity: a prospective randomized controlled trial. <i>Blood Pressure</i> , <b>2014</b> , 23, 54-60	0.4	7
220	Double-Dose Versus Standard-Dose Clopidogrel According to Smoking Status Among Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	1.4	7
219	The cost implications of an early versus delayed invasive strategy in Acute Coronary Syndromes: the TIMACS study. <i>Journal of Medical Economics</i> , <b>2014</b> , 17, 415-22	0.6	7
218	Fine mapping of the insulin-induced gene 2 identifies a variant associated with LDL cholesterol and total apolipoprotein B levels. <i>Circulation: Cardiovascular Genetics</i> , <b>2010</b> , 3, 454-61		7
217	Is therapy of people with chronic kidney disease ONTARGET?. <i>Nephrology Dialysis Transplantation</i> , <b>2010</b> , 25, 42-4	1.2	7

216	Deciphering the causes of cardiovascular and other complex diseases in populations: achievements, challenges, opportunities, and approaches. <i>Progress in Cardiovascular Diseases</i> , <b>2010</b> , 53, 62-7	1.9	7
215	Stroke and cardiovascular diseases: the need for a global approach for prevention and drug development. <i>International Journal of Stroke</i> , <b>2007</b> , 2, 104-8	2	7
214	Clinical decisions. Management of stable coronary disease. <i>New England Journal of Medicine</i> , <b>2007</b> , 357, 1762-6	18	7
213	Limitation of myocardial infarct size. Present status. <i>Drugs</i> , <b>1983</b> , 25, 441-50	3.3	7
212	Are large simple trials for dementia prevention possible?. <i>Age and Ageing</i> , <b>2020</b> , 49, 154-160	1	7
211	Could patents interfere with the development of a cardiovascular polypill?. <i>Journal of Translational Medicine</i> , <b>2016</b> , 14, 242	2.3	7
210	Adapting the World Heart Federation Roadmaps at the National Level: Next Steps and Conclusions. <i>Global Heart</i> , <b>2015</b> , 10, 135-6	1.1	7
209	Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. <i>Cardiovascular Research</i> , <b>2021</b> , 117, 942-949	2.5	7
208	Digoxin and clinical outcomes in the Global Rheumatic Heart Disease Registry. <i>Heart</i> , <b>2019</b> , 105, 363-369	1.3	7
207	Dietary Saturated Fats and Health: Are the U.S. Guidelines Evidence-Based?. <i>Nutrients</i> , <b>2021</b> , 13,	2	7
206	Multi-ancestry genetic study of type 2 diabetes highlights the power of diverse populations for discovery and translation.. <i>Nature Genetics</i> , <b>2022</b> ,	7	7
205	A multinational registry to study the characteristics and outcomes of heart failure patients: The global congestive heart failure (G-CHF) registry. <i>American Heart Journal</i> , <b>2020</b> , 227, 56-63	1.3	6
204	Efficacy and safety of dabigatran compared with warfarin in patients with atrial fibrillation in relation to renal function over time-A RE-LY trial analysis. <i>American Heart Journal</i> , <b>2018</b> , 198, 169-177	1.3	6
203	Insulin resistance and cardiovascular outcomes in the ORIGIN trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2018</b> , 20, 564-570	1.7	6
202	Associations of cardiometabolic outcomes with indices of obesity in children aged 5 years and younger. <i>PLoS ONE</i> , <b>2019</b> , 14, e0218816	1.2	6
201	Impact of lifestyle factors on fracture risk in older patients with cardiovascular disease: a prospective cohort study of 26,335 individuals from 40 countries. <i>Age and Ageing</i> , <b>2014</b> , 43, 629-35	1	6
200	Physical Activity to Prevent Cardiovascular Disease: A Simple, Low-Cost, and Widely Applicable Approach for All Populations. <i>JAMA Cardiology</i> , <b>2017</b> , 2, 1358-1360	4	6
199	Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2015</b> , 100, 2682-9	1.5	6

198	Cigarette pack labelling in 12 countries at different levels of economic development. <i>Journal of Public Health Policy</i> , <b>2011</b> , 32, 146-64	1.1	6
197	Dysglycaemia and risk of cardiovascular disease. <i>Lancet, The</i> , <b>1996</b> , 347, 1833-4	11.5	6
196	ATENOLOL, HEPARIN AND THE INTERMEDIATE CORONARY SYNDROME. <i>Lancet, The</i> , <b>1981</b> , 318, 46	11.5	6
195	Management and Outcomes of Major Bleeding On Dabigatran or Warfarin. <i>Blood</i> , <b>2012</b> , 120, 19-19	0.6	6
194	Rationale and design of a cluster randomized trial of a multifaceted intervention in people with hypertension: The Heart Outcomes Prevention and Evaluation 4 (HOPE-4) Study. <i>American Heart Journal</i> , <b>2018</b> , 203, 57-66	1.3	6
193	COVID-19 Vaccination Prioritization on the Basis of Cardiovascular Risk Factors and Number Needed to Vaccinate to Prevent Death. <i>Canadian Journal of Cardiology</i> , <b>2021</b> , 37, 1112-1116	1.3	6
192	Sodium Intake and Health: What Should We Recommend Based on the Current Evidence?. <i>Nutrients</i> , <b>2021</b> , 13,	2	6
191	Tranexamic Acid in Patients Undergoing Noncardiac Surgery.. <i>New England Journal of Medicine</i> , <b>2022</b> ,	18	6
190	Influence of tea consumption on acute myocardial infarction in China population: the INTERHEART China study. <i>Angiology</i> , <b>2015</b> , 66, 265-70	0.6	5
189	Overestimation of Stroke Risk in Rheumatic Mitral Stenosis and the Implications for Oral Anticoagulation. <i>Circulation</i> , <b>2020</b> , 142, 1697-1699	4.8	5
188	Serial measurement of interleukin-6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE-LY trials. <i>Journal of Thrombosis and Haemostasis</i> , <b>2020</b> , 18, 2287-2295	3	5
187	Reduced Cognitive Assessment Scores Among Individuals With Magnetic Resonance Imaging-Detected Vascular Brain Injury. <i>Stroke</i> , <b>2020</b> , 51, 1158-1165	1.8	5
186	A Risk Assessment Tool Incorporating New Biomarkers for Cardiovascular Events in Acute Coronary Syndromes: The Organization to Assess Strategies in Ischemic Syndromes (OASIS) Risk Score. <i>Canadian Journal of Cardiology</i> , <b>2016</b> , 32, 1332-1339	1.3	5
185	Varying Effects of Body Mass Index and Mortality in Different Risk Groups. <i>American Journal of Cardiology</i> , <b>2018</b> , 122, 1155-1160	0.7	5
184	Risk factors for stroke in Tanzania. <i>The Lancet Global Health</i> , <b>2013</b> , 1, e241-2	4	5
183	Effective approaches to address the global cardiovascular disease burden. <i>Current Opinion in Cardiology</i> , <b>2017</b> , 32, 557-566	0.6	5
182	Gene Expression Profiles for the Identification of Prevalent Atrial Fibrillation. <i>Journal of the American Heart Association</i> , <b>2017</b> , 6,	1.4	5
181	Does greater individual social capital improve the management of hypertension? Cross-national analysis of 61 229 individuals in 21 countries. <i>BMJ Global Health</i> , <b>2017</b> , 2, e000443	2.1	5

180	The cost of clopidogrel use in atrial fibrillation in the ACTIVE-A trial. <i>Canadian Journal of Cardiology</i> , <b>2012</b> , 28, 95-101	1.3	5
179	Unresolved issues in the management of hypertension. <i>Hypertension</i> , <b>2010</b> , 55, 832-4	2.4	5
178	Association of the FABP2 T54 variant with plasma triglycerides and insulin resistance in a multiethnic population. <i>Clinical Chemistry</i> , <b>2008</b> , 54, 1742-4	1.4	5
177	Corrigendum to Effectiveness of comprehensive disease management programmes in improving clinical outcomes in heart failure patients. A meta-analysis [Eur J Heart Fail 7 (2005) 1133-1144]. <i>European Journal of Heart Failure</i> , <b>2006</b> , 8, 223-224	3.1	5
176	Oral anticoagulant therapy in patients with coronary artery disease. <i>Seminars in Vascular Medicine</i> , <b>2003</b> , 3, 323-32		5
175	The impact of left ventricular dysfunction on outcomes with the implantable defibrillator. <i>American Heart Journal</i> , <b>1994</b> , 127, 1159-63	1.3	5
174	Renin response to sympathetic stimulation in cyclosporin-treated heart-transplant patients. <i>American Journal of Cardiology</i> , <b>1989</b> , 63, 1142-4	0.7	5
173	One-year Results of a Factorial Randomized Trial of Aspirin versus Placebo and Clonidine versus Placebo in Patients Having Noncardiac Surgery. <i>Anesthesiology</i> , <b>2020</b> , 132, 692-701	1.2	5
172	Rivaroxaban for Prevention of Covert Brain Infarcts and Cognitive Decline: The COMPASS MRI Substudy. <i>Stroke</i> , <b>2020</b> , 51, 2901-2909	1.8	5
171	Fruit, vegetable, and legume intake and the risk of all-cause, cardiovascular, and cancer mortality: A prospective study. <i>Clinical Nutrition</i> , <b>2021</b> , 40, 4316-4323	1.5	5
170	New-Onset Perioperative Atrial Fibrillation After Coronary Artery Bypass Grafting and Long-Term Risk of Adverse Events: An Analysis From the CORONARY Trial. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e020426	1.4	5
169	Challenges to conducting epidemiology research in chronic conflict areas: examples from PURE-Palestine. <i>Conflict and Health</i> , <b>2016</b> , 10, 33	0.9	5
168	Low sodium intake and cardiovascular health: an unanswered question. Response to: Letter from Dr N. Campbell, 'Dissidents and dietary sodium. Concerns about the commentary by O'Donnell et al.'. <i>International Journal of Epidemiology</i> , <b>2017</b> , 46, 367-369	1.9	5
167	Blood-Pressure and Cholesterol Lowering in the HOPE-3 Trial. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 1193-4	1.8	5
166	Cardiovascular risk scoring and magnetic resonance imaging detected subclinical cerebrovascular disease. <i>European Heart Journal Cardiovascular Imaging</i> , <b>2020</b> , 21, 692-700	1	5
165	The Effect of Steroids in Patients Undergoing Cardiopulmonary Bypass: An Individual Patient Meta-Analysis of Two Randomized Trials. <i>Journal of Cardiothoracic and Vascular Anesthesia</i> , <b>2020</b> , 34, 99-105	0.4	5
164	"Cerebral small vessel disease and other influential factors of cognitive impairment in the middle-aged: a long-term observational cohort PURE-MIND study in Poland". <i>GeroScience</i> , <b>2021</b> , 43, 279-295	1.9	5
163	Multiplex protein screening of biomarkers associated with major bleeding in patients with atrial fibrillation treated with oral anticoagulation. <i>Journal of Thrombosis and Haemostasis</i> , <b>2021</b> , 19, 2726-2737	3	5

162	Graphical comparisons of relative disease burden across multiple risk factors. <i>BMC Medical Research Methodology</i> , <b>2019</b> , 19, 186	1.1	4
161	Reasons for hospitalization and risk of mortality in patients with atrial fibrillation treated with dabigatran or warfarin in the Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) trial. <i>Europace</i> , <b>2019</b> , 21, 1023-1030	1	4
160	Risks of Overinterpreting Interim Data: Lessons From the TOTAL Trial (Thrombectomy With PCI Versus PCI Alone in Patients With STEMI). <i>Circulation</i> , <b>2018</b> , 137, 206-209	4.8	4
159	Polypill Variants (Quarter Pill Trials). <i>American Journal of Hypertension</i> , <b>2018</b> , 31, 758-761	0.7	4
158	Impact of access to hospitals with catheterization facilities in the second Gulf Registry of Acute Coronary Events (Gulf RACE-2). <i>Coronary Artery Disease</i> , <b>2013</b> , 24, 412-8	0.3	4
157	The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study. <i>Journal of Medical Economics</i> , <b>2011</b> , 14, 792-7	0.6	4
156	Cardiovascular Outcomes and Renal Disease. <i>Annals of Internal Medicine</i> , <b>2002</b> , 136, 634	2.5	4
155	Role of infarct size in explaining the higher mortality in older patients with acute myocardial infarction. <i>American Journal of Cardiology</i> , <b>2002</b> , 90, 1370-4	0.7	4
154	Effects of ACE inhibitors on mortality when started in the early phase of myocardial infarction: evidence from the larger randomized controlled trials. <i>European Journal of Cardiovascular Prevention and Rehabilitation</i> , <b>1995</b> , 2, 423-8		4
153	Urinary Sodium and Potassium, and Risk of Ischemic and Hemorrhagic Stroke (INTERSTROKE): A Case-Control Study. <i>American Journal of Hypertension</i> , <b>2021</b> , 34, 414-425	0.7	4
152	Effect of Cognitive Reserve on the Association of Vascular Brain Injury With Cognition: Analysis of the PURE and CAHHM Studies. <i>Neurology</i> , <b>2021</b> , 97, e1707-e1716	1.7	4
151	Monitoring Emerging Data From the COMPASS Trial of an Antithrombotic Agent. <i>Journal of the American College of Cardiology</i> , <b>2019</b> , 73, 2769-2772	3.8	3
150	Cardiovascular risk and events and country income stratum. <i>New England Journal of Medicine</i> , <b>2015</b> , 372, 290	18	3
149	Associations of fats and carbohydrates with cardiovascular disease and mortality-PURE and simple? - Authors' reply. <i>Lancet, The</i> , <b>2018</b> , 391, 1681-1682	11.5	3
148	Response to: 'More on dissidents and dietary sodium'. <i>International Journal of Epidemiology</i> , <b>2018</b> , 47, 673-674	1.9	3
147	Identification of Novel Causal Blood Biomarkers Linking Metabolically Favorable Adiposity With Type 2 Diabetes Risk. <i>Diabetes Care</i> , <b>2019</b> , 42, 1800-1808	3.9	3
146	Reply: regarding the effect of dabigatran plasma concentrations. <i>Journal of the American College of Cardiology</i> , <b>2014</b> , 63, 2885-6	3.8	3
145	Commentary: 'The end of clinical freedom': relevance in the era of evidence-based medicine. <i>International Journal of Epidemiology</i> , <b>2011</b> , 40, 855-8	1.9	3

144	Independent design and conduct of clinical trials. <i>Clinical Trials</i> , <b>2006</b> , 3, 503-7	0.6	3
143	The CHARM programme. <i>Lancet, The</i> , <b>2003</b> , 362, 1678-1679	11.5	3
142	Randomized trials to assess the long-term effects of therapies on angiographic end points. <i>Chest</i> , <b>1991</b> , 99, 1243-7	1.2	3
141	Population Muscle Strength Predicts Olympic Medal Tallies: Evidence from 20 Countries in the PURE Prospective Cohort Study. <i>PLoS ONE</i> , <b>2017</b> , 12, e0169821	1.2	3
140	Anger or emotional upset and heavy physical exertion as triggers of stroke: the INTERSTROKE study. <i>European Heart Journal</i> , <b>2021</b> ,	3.5	3
139	Associations of estimated 24-h urinary sodium excretion with mortality and cardiovascular events in Chinese adults: a prospective cohort study. <i>Journal of Hypertension</i> , <b>2021</b> , 39, 484-493	0.5	3
138	Associations of household solid fuel for heating and cooking with hypertension in Chinese adults. <i>Journal of Hypertension</i> , <b>2021</b> , 39, 667-676	0.5	3
137	Association of bedtime with mortality and major cardiovascular events: an analysis of 112,198 individuals from 21 countries in the PURE study. <i>Sleep Medicine</i> , <b>2021</b> , 80, 265-272	1.3	3
136	Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. <i>European Heart Journal</i> , <b>2021</b> , 42, 2995-3007	3.5	3
135	Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). <i>American Journal of Cardiology</i> , <b>2021</b> , 149, 27-35	0.7	3
134	Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. <i>Journal of the American College of Cardiology</i> , <b>2021</b> , 77, 511-525	3.8	3
133	Diabetes, Brain Infarcts, Cognition, and Small Vessels in the Canadian Alliance for Healthy Hearts and Minds Study. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2021</b> , 106, e891-e898	1.5	3
132	High-Sensitivity Troponin I after Cardiac Surgery and 30-Day Mortality.. <i>New England Journal of Medicine</i> , <b>2022</b> , 386, 827-836	18	3
131	Sodium and cardiovascular disease - Authors' reply. <i>Lancet, The</i> , <b>2016</b> , 388, 2113-2114	11.5	2
130	A 35-year journey to evidence-based medicine: a personal story. <i>European Heart Journal</i> , <b>2015</b> , 36, 3460-6.5	9.5	2
129	Corrigendum to Analysing recurrent hospitalizations in heart failure: a review of statistical methodology, with application to CHARM-Preserved [Eur J Heart Fail 2014;16:3340]. <i>European Journal of Heart Failure</i> , <b>2014</b> , 16, 592-592	3.1	2
128	Response to letters regarding article, Peri-procedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) Randomized Trial [Circulation, <b>2013</b> , 127, e506	4.8	2
127	The Editor's Roundtable: arterial thrombosis and acute coronary syndromes. <i>American Journal of Cardiology</i> , <b>2007</b> , 100, 974-80	0.7	2

126	Does treatment with rosiglitazone increase cardiovascular risk of patients with type 2 diabetes mellitus?. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , <b>2007</b> , 3, 798-9		2
125	Blood pressure and cardiovascular risk in the HOPE study. <i>Lancet, The</i> , <b>2002</b> , 359, 2118	11.5	2
124	Intracranial haemorrhage with bolus thrombolytic agents. <i>Lancet, The</i> , <b>2000</b> , 356, 1850	11.5	2
123	Effect of acute angiotensin converting enzyme inhibition on left ventricular diastolic filling in patients with congestive heart failure: Relation to right ventricular volume. <i>Journal of the American College of Cardiology</i> , <b>1990</b> , 15, A210	3.8	2
122	Risk-benefit assessment of antiarrhythmic drugs. An epidemiological perspective. <i>Drug Safety</i> , <b>1991</b> , 6, 323-31	1.1	2
121	Evaluation of Adiposity and Cognitive Function in Adults.. <i>JAMA Network Open</i> , <b>2022</b> , 5, e2146324	2.9	2
120	Low levels of awareness, treatment, and control of hypertension in Andean communities of Ecuador. <i>Journal of Clinical Hypertension</i> , <b>2020</b> , 22, 1530-1537	0.6	2
119	Rosuvastatin for the prevention of venous thromboembolism: a pooled analysis of the HOPE-3 and JUPITER randomized controlled trials. <i>Cardiovascular Research</i> , <b>2021</b> ,	2.5	2
118	Impact of blood pressure lowering, cholesterol lowering and their combination in Asians and non-Asians in those without cardiovascular disease: an analysis of the HOPE 3 study. <i>European Journal of Preventive Cardiology</i> , <b>2019</b> , 26, 681-697	1.2	2
117	Long-Term Treatment with Apixaban in Patients with Atrial Fibrillation: Outcomes during the Open-Label Extension following AVERROES. <i>Thrombosis and Haemostasis</i> , <b>2021</b> , 121, 518-528	1.8	2
116	Acute non-ST-segment Elevation Coronary Syndromes: Unstable Angina and non-ST-segment Elevation Myocardial Infarction 397-425		2
115	Pericardial Disease: An Evidence-Based Approach to Diagnosis and Treatment 735-748		2
114	Identification of genetic effects underlying type 2 diabetes in South Asian and European populations.. <i>Communications Biology</i> , <b>2022</b> , 5, 329	1.9	2
113	Mitochondrial DNA Copy Number as a Marker and Mediator of Stroke Prognosis: Observational and Mendelian Randomization Analyses. <i>Neurology</i> , <b>2021</b> ,	1.7	2
112	Response by Smyth et al to Letters Regarding Article, "Physical Activity and Anger or Emotional Upset as Triggers of Acute Myocardial Infarction: The INTERHEART Study". <i>Circulation</i> , <b>2017</b> , 135, e644-e645	4.8	1
111	On the economics of managing blood pressure. <i>Lancet, The</i> , <b>2017</b> , 389, 1294-1295	11.5	1
110	Effects of basal insulin glargine and omega-3 on lower limb arterial disease outcome in patients with dysglycaemia: An analysis of the Outcome Reduction with an Initial Glargine INTERvention (ORIGIN) trial. <i>Diabetes, Obesity and Metabolism</i> , <b>2019</b> , 21, 1502-1505	1.7	1
109	Facing cardiovascular risk in Ibero-America. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2020</b> , 73, 799-8012		1



108	WHF Emerging Leaders Program. <i>European Heart Journal</i> , <b>2017</b> , 38, 2800-2803	3.5	1
107	Improving worldwide access to inexpensive and effective treatments for common cardiovascular diseases. <i>European Heart Journal Supplements</i> , <b>2018</b> , 20, C18-C22	0.4	1
106	Effects of Lipid-Lowering and Antihypertensive Treatments in Addition to Healthy Lifestyles in Primary Prevention: An Analysis of the HOPE-3 Trial. <i>Journal of the American Heart Association</i> , <b>2018</b> , 7,	1.4	1
105	Response to letter regarding article, "Efficacy and safety of dabigatran compared with warfarin in relation to baseline renal function in patients with atrial fibrillation: a RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) trial analysis". <i>Circulation</i> , <b>2014</b> , 130, e195	4.8	1
104	Response to letter regarding article, "Causes of death and influencing factors in patients with atrial fibrillation: a competing-risk analysis from the randomized evaluation of long-term anticoagulant therapy study". <i>Circulation</i> , <b>2014</b> , 130, e85	4.8	1
103	Response to letter regarding article, "Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: a randomized evaluation of long-term anticoagulation therapy (RE-LY) substudy". <i>Circulation</i> , <b>2013</b> , 127, e278-9	4.8	1
102	Meta-analysis. <i>Lancet, The</i> , <b>1998</b> , 351, 1960	11.5	1
101	Risk Factors for Early Myocardial Infarction in South AsiansReply. <i>JAMA - Journal of the American Medical Association</i> , <b>2007</b> , 297, 1880	7.4	1
100	The value of large, robust trials: the HOPE study. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , <b>2002</b> , 19, 29-30		1
99	Commentary: insights from cross-population studies: Rose revisited. <i>International Journal of Epidemiology</i> , <b>2005</b> , 34, 244-6	1.9	1
98	Management of unstable angina and myocardial infarction. <i>Lancet, The</i> , <b>2000</b> , 356, 1193-1194	11.5	1
97	Randomized Clinical Trials in Heart Disease-Reply. <i>JAMA - Journal of the American Medical Association</i> , <b>1989</b> , 261, 2953	7.4	1
96	The likelihood ratio versus the p value in meta-analysis: where is the evidence? Comment on the paper by S. N. Goodman. <i>Contemporary Clinical Trials</i> , <b>1989</b> , 10, 205-8; discussion 209-10		1
95	Rationale and design of the PeriOperative ISchemic Evaluation-3 (POISE-3): a randomized controlled trial evaluating tranexamic acid and a strategy to minimize hypotension in noncardiac surgery.. <i>Trials</i> , <b>2022</b> , 23, 101	0.8	1
94	Differences and agreement between two portable hand-held spirometers across diverse community-based populations in the Prospective Urban Rural Epidemiology (PURE) study. <i>PLOS Global Public Health</i> , <b>2022</b> , 2, e0000141	0.5	1
93	Variations in risks from smoking between high-income, middle-income, and low-income countries: an analysis of data from 179 000 participants from 63 countries.. <i>The Lancet Global Health</i> , <b>2022</b> , 10, e218 <sup>4</sup> -e226 <sup>1</sup>		1
92	Variations in the financial impact of the COVID-19 pandemic across 5 continents: A cross-sectional, individual level analysis.. <i>EClinicalMedicine</i> , <b>2022</b> , 44, 101284	3.7	1
91	Restenosis: Etiologies and Prevention371-394		1

90	Risk of cardiovascular events in patients with metabolic syndrome: Results of a population-based prospective cohort study (PURE Turkey). <i>Anatolian Journal of Cardiology</i> , <b>2020</b> , 24, 192-200	0.2	1
89	What is the Association Between Depression and Cardiovascular Disease?-Reply. <i>JAMA Psychiatry</i> , <b>2020</b> , 77, 1308-1309	4.5	1
88	Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , <b>2021</b> ,	1.2	1
87	Timing and Length of Nocturnal Sleep and Daytime Napping and Associations With Obesity Types in High-, Middle-, and Low-Income Countries. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2113775	2.9	1
86	Renal Impairment and Risk of Acute Stroke: The INTERSTROKE Study. <i>Neuroepidemiology</i> , <b>2021</b> , 55, 206-215	2.65	1
85	Adiposity and mortality in South Asians: challenges to the existing paradigm. <i>The Lancet Global Health</i> , <b>2018</b> , 6, e712-e713	4	1
84	Prevalence of metabolic syndrome and diabetes mellitus type-2 and their association with intake of dairy and legume in Andean communities of Ecuador. <i>PLoS ONE</i> , <b>2021</b> , 16, e0254812	1.2	1
83	Antihypertensives and Statin Therapy for Primary Stroke Prevention: A Secondary Analysis of the HOPE-3 Trial. <i>Stroke</i> , <b>2021</b> , 52, 2494-2501	1.8	1
82	Measuring sodium intake: research and clinical applications. <i>Journal of Hypertension</i> , <b>2021</b> , 39, 2344-2352.	2.5	1
81	LVS-HARMED Risk Score for Incident Heart Failure in Patients With Atrial Fibrillation Who Present to the Emergency Department: Data from a World-Wide Registry. <i>Journal of the American Heart Association</i> , <b>2021</b> , 10, e017735	1.4	1
80	Does a High-inflammatory Diet Increase the Risk of Inflammatory Bowel Disease? Results From the Prospective Urban Rural Epidemiology (PURE) Study: A Prospective Cohort Study. <i>Gastroenterology</i> , <b>2021</b> , 161, 1333-1335.e1	3.1	1
79	Blood Pressure and Cardiovascular Disease	146-160	1
78	The Fetal Origins of Coronary Heart Disease	279-286	1
77	Management of Overt Heart Failure	659-680	1
76	Polypharmacotherapy for primary prevention of cardiovascular disease. <i>Indian Heart Journal</i> , <b>2008</b> , 60, B29-33	0.4	1
75	Psychosocial Risk Factors and Cardiovascular Disease and Death in a Population-Based Cohort From 21 Low-, Middle-, and High-Income Countries.. <i>JAMA Network Open</i> , <b>2021</b> , 4, e2138920	2.9	1
74	Psychosocial Factors in the Primary and Secondary Prevention of Coronary Heart Disease: An Updated Systematic Review of Prospective Cohort Studies	181-218	1
73	Intensive insulin-glucose infusion regimens with long-term or standard glucose control did not differ for reducing mortality in type 2 diabetes mellitus and MI. <i>ACP Journal Club</i> , <b>2005</b> , 143, 43		1

72	Statin Use in Primary Prevention: A Simple Trial-Based Approach Compared With Guideline-Recommended Risk Algorithms for Selection of Eligible Patients. <i>Canadian Journal of Cardiology</i> , <b>2019</b> , 35, 644-652	1.3	0
71	Eggs and diabetes: 1 daily egg a safe bet?. <i>American Journal of Clinical Nutrition</i> , <b>2020</b> , 112, 503-504	1.8	0
70	Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study. <i>PLoS ONE</i> , <b>2020</b> , 15, e0226259	1.2	0
69	Leaders in Cardiovascular Research: Salim Yusuf. <i>Cardiovascular Research</i> , <b>2020</b> , 116, e26-e28	2.5	0
68	Preface: Reflections on a Career in Health Research, International Collaboration and Mentoring. <i>Public Health Reviews</i> , <b>2011</b> , 33, 363-372	1.5	0
67	Renal outcomes in the ONTARGET study [Authors' reply]. <i>Lancet, The</i> , <b>2008</b> , 372, 2020-2021	11.5	0
66	Who is fooling us?. <i>Lancet, The</i> , <b>2002</b> , 360, 873-4	11.5	0
65	Association between exercise frequency with renal and cardiovascular outcomes in diabetic and non-diabetic individuals at high cardiovascular risk.. <i>Cardiovascular Diabetology</i> , <b>2022</b> , 21, 12	2.5	0
64	Bongani Mayosi, a hero remembered. <i>Cardiovascular Journal of Africa</i> , <b>2018</b> , 29, 206	0.1	0
63	Measuring and predicting personal and household Black Carbon levels from 88 communities in eight countries. <i>Science of the Total Environment</i> , <b>2021</b> , 818, 151849	3.9	0
62	Multinational prediction of household and personal exposure to fine particulate matter (PM) in the PURE cohort study.. <i>Environment International</i> , <b>2021</b> , 159, 107021	4.7	0
61	Cardiovascular consequences of discontinuing low-dose rivaroxaban in people with chronic coronary or peripheral artery disease. <i>Heart</i> , <b>2021</b> , 107, 1130-1137	1.3	0
60	Exploring New Models for Cardiovascular Risk Reduction: The Heart Outcomes Prevention and Evaluation 4 (HOPE 4) Canada Pilot Study. <i>CJC Open</i> , <b>2021</b> , 3, 267-275	0.5	0
59	Causal ordering among risk factors in the PURE study - Authors' reply. <i>Lancet, The</i> , <b>2021</b> , 397, 279	11.5	0
58	Risk stratification of cardiovascular complications using CHADS-VASc and CHADS scores in chronic atherosclerotic cardiovascular disease. <i>International Journal of Cardiology</i> , <b>2021</b> , 337, 9-15	0.8	0
57	Rivaroxaban versus aspirin on functional and cognitive outcomes after embolic stroke of undetermined source: NAVIGATE ESUS trial.. <i>Journal of Stroke and Cerebrovascular Diseases</i> , <b>2022</b> , 31, 106404	0.8	0
56	Personal and household PM and black carbon exposure measures and respiratory symptoms in 8 low- and middle-income countries.. <i>Environmental Research</i> , <b>2022</b> , 212, 113430	3.1	0
55	The INTERSTROKE study on risk factors for stroke - Authors' reply. <i>Lancet, The</i> , <b>2017</b> , 389, 36	11.5	0

54	The MANAGE trial - Authors' reply. <i>Lancet, The</i> , <b>2019</b> , 393, 228	11.5
53	Response to letter regarding article, "Management and outcomes of major bleeding during treatment with dabigatran or warfarin". <i>Circulation</i> , <b>2014</b> , 130, e95	4.8
52	The preventive potential of common, easily measured risk factors for cardiovascular disease. <i>Clinical Chemistry</i> , <b>2014</b> , 60, 1450-1	1.4
51	Selection of patients for angiography following myocardial infarction was not based on risk but on young age and availability of angiographic facilities. <i>Evidence-based Cardiovascular Medicine</i> , <b>1997</b> , 1, 52	
50	Fondaparinux in Patients With ST-Segment Elevation Myocardial Infarction Reply. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 296, 2087	7.4
49	INTERHEART. <i>Lancet, The</i> , <b>2005</b> , 365, 119-120	11.5
48	Recommendations for national and local regulatory authorities concerning research in genetic markers of disease. <i>American Heart Journal</i> , <b>2000</b> , 140, S3-5	1.3
47	Homocysteine and cardiovascular risk: is it time to treat?. <i>Evidence-based Cardiovascular Medicine</i> , <b>1999</b> , 3, 59-60	
46	Design of trials to evaluate antiplatelet agents <b>2002</b> , 1003-1012	
45	Peter Sleight, Emeritus Professor of Cardiovascular Medicine, Oxford University, Chairman of the ISIS Trials Steering Committee. <i>European Heart Journal</i> , <b>2021</b> , 42, 221-223	3.5
44	Reply. <i>Gastroenterology</i> , <b>2020</b> , 158, 285-286	3.1
43	Cardiovascular risk in hypertension: open questions about HOPE 4 - Authors' reply. <i>Lancet, The</i> , <b>2020</b> , 396, 310-311	11.5
42	Fishing for an Association With Sudden Cardiac Death-Reply. <i>JAMA Internal Medicine</i> , <b>2021</b> , 181, 1140-1141	11.1
41	A cardiovascular study that includes a million subjects. <i>European Heart Journal</i> , <b>2013</b> , 34, 945-6	3.5
40	Tobacco: Global Burden and Community Solutions 103-113	
39	Glucose Abnormalities and Cardiovascular Disease: Dysglycemia as an Emerging Cardiovascular Risk Factor 161-169	
38	Physical Activity and Exercise in Cardiovascular Disease Prevention and Rehabilitation 170-180	
37	A Critical Appraisal of the Cardiovascular History and Physical Examination 14-23	

- 36 Molecular Genetics of Cardiovascular Disorders 287-299
- 35 Adjunctive Medical Therapy in Percutaneous Coronary Intervention 360-370
- 34 Fibrinolytic Therapy 426-443
- 33 Mechanical Reperfusion Strategies in Patients Presenting with Acute Myocardial Infarction 444-455
- 32 Adjunctive Antithrombotic Therapy for St-Elevation Acute Myocardial Infarction 456-476
- 31 Pain Relief, General Management, and Other Adjunctive Treatments 477-487
- 30 Complications After Myocardial Infarction 488-506
- 29 Atrial Fibrillation: Antiarrhythmic Therapy 519-547
- 28 Atrial Fibrillation: Non-Pharmacologic Therapies 556-566
- 27 Prevention and Treatment of Life-Threatening Ventricular Arrhythmia and Sudden Death 577-586
- 26 Impact of Pacemakers: When and What Kind? 587-618
- 25 Acute Myocarditis and Dilated Cardiomyopathy 681-702
- 24 Other Cardiomyopathies 718-732
- 23 Finding Current Best Evidence to Practice Evidence-Based Cardiology 40-45
- 22 Rheumatic Heart Disease: Prevention and Acute Treatment 751-757
- 21 Indications for Surgery in Aortic Valve Disease 767-781
- 20 Balloon Valvuloplasty: Aortic Valve 782-795
- 19 Valve Repair and Choice of Valves 809-816

- 18 Diagnosis and Management of Infective Endocarditis 817-831
- 17 Antithrombotic Therapy after Heart Valve Replacement 832-836
- 16 Heart Disease and Pregnancy 853-863
- 15 Venous Thromboembolic Disease 864-876
- 14 Introduction to Decision Analysis 56-70
- 13 Valvular Heart Disease: Timing of Surgery 934-937
- 12 Assessing and Changing Cardiovascular Clinical Practices 71-88
- 11 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology 1-2
- 10 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology 837-838
- 9 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology 887-888
- 8 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology 89-90
- 7 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology 327-328
- 6 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology 395-396
- 5 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology 517-518
- 4 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology 575-576
- 3 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology 641-642
- 2 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology 733-734
- 1 Grading of Recommendations and Levels of Evidence Used in Evidence-based Cardiology 749-750

